| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | garetosmab fibrodysplasia ossificans progressiva (FOP) | BLA | — | Biologics | Rare Diseases | ||
BLA Submission example | garetosmab fibrodysplasia ossificans progressiva (FOP) | BLA | — | Biologics | Rare Diseases | ||
BLA Submission example | garetosmab fibrodysplasia ossificans progressiva (FOP) | BLA | — | Biologics | Rare Diseases |
Recent Updates
Recently added Catalysts
Regeneron Pharmaceuticals, Inc.$624.72
+1.18 (+0.19%)
A 88Pipeline Score Fair Value Pharma · Commercial
Market Cap
66.98 B
EPS
42.53
P/E Ratio
15.57 $
Value Trade
609.23 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.61 B
R&D Expenses
1.54 B
Operating CF
1.08 B
Total Assets
40.87 B
Total Liabilities
9.45 B
Equity
31.42 B
D/E Ratio
12,345
-10.36 %
Week
-14.98 %
1 Month
-17.56 %
3 Month
-13.2 %
6 Month
24.26 %
5 Year
2,924.28 %
All Time
Cash Data
Cash Position
8.75 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
1.06 M
52 Week Range
476.49 - 821.11
% held by Insiders
3.78 %
% held by Institutions
88.19 %
Enterprise Value
60.92 B
Total Shares
103.94 M
Short %
3.28 %
Float Shares
98.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Regeneron Pharmaceuticals, Inc.
954Total events
32Upcoming
542Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 32
Q4 2026
T1Topline Readout
Report results from Phase 3 study for pozelimab in combination with cemdisiran in PNH
TBD
T2Trial Completion
Open-label extension through week 128 ongoing; further assessments at week 76 and 128
TBD
T2Other Regulator Milestone
Additional submissions planned to other regulatory authorities for Dupixent in AFRS
TBD
T3Enrollment Update
CHORD trial currently enrolling children (<18 years) across sites in US, UK, Spain, Germany, Japan
2026-H2
T1Interim Analysis
Second interim analysis and final analysis for fianlimab in adjuvant melanoma anticipated in H2 2026
2026-H2
T1Topline Readout
Report initial results from lead-in cohort of Phase 3 study for cemdisiran as monotherapy and in combination with pozelimab in geographic atrophy
2026-H1
T2Trial Initiation
Initiate second Phase 3 study for REGN1908-1909 (Fel d 1 multi-antibody) in cat allergy
2026-H1
T2Trial Initiation
Initiate additional Phase 3 studies for Factor XI antibodies (REGN7508 and REGN9933) in anticoagulation
2026-H1
T1Topline Readout
Report results from Phase 3 study for fianlimab in combination with Libtayo versus pembrolizumab in first-line metastatic melanoma
2026-H1
T2Trial Initiation
Initiate additional Phase 3 studies for Factor XI antibodies in anticoagulation
Event history 922
May 29, 2026
◆Oral PresentationlinvoseltamabApprovedPresentation
Oral presentation of LINKER-AL2 results at ASCO 2026
systemic amyloid light chain (AL) amyloidosissource ↗
May 28, 2026
▲Other Regulator MilestonemaftivimabEx-US Regulatory
WHO Therapeutics Advisory Group recommends maftivimab for evaluation in clinical trials for Bundibugyo ebolavirus
Bundibugyo ebolavirussource ↗
May 22, 2026
▲EU MAA SubmissionOtarmeniApprovedEx-US Regulatory
EMA accepts MAA for Otarmeni under Accelerated Assessment
biallelic OTOF variant-associated hearing losssource ↗
May 22, 2026
▲EMA Accelerated AssessmentOtarmeniApprovedEx-US Regulatory
Accelerated Assessment granted by EMA for Otarmeni MAA
biallelic OTOF variant-associated hearing losssource ↗
May 21, 2026
▲Topline ReadoutlinvoseltamabApprovedClinical Data
Preliminary analysis results from LINKER-AL2: 100% hematologic CR at highest dose
systemic amyloid light chain (AL) amyloidosissource ↗
May 5, 2026
▲Oral PresentationdupilumabApprovedPresentation
Late-breaking oral presentation of REMODEL Phase 4 trial results at DDW 2026
Eosinophilic Esophagitissource ↗
May 5, 2026
▲Topline ReadoutdupilumabApprovedClinical Data
Primary endpoint met: improvement in esophageal distensibility plateau at week 24
Eosinophilic Esophagitissource ↗
May 5, 2026
▲Primary Endpoint MetdupilumabApprovedClinical Data
Primary endpoint met: esophageal distensibility plateau improvement
Eosinophilic Esophagitissource ↗
May 5, 2026
▲Full ResultsdupilumabApprovedClinical Data
Full results of REMODEL Phase 4 trial presented at DDW
Eosinophilic Esophagitissource ↗
Apr 29, 2026
Apr 23, 2026
▲FDA ApprovalOtarmeniApprovedFDA Decision
FDA granted accelerated approval for Otarmeni
severe-to-profound and profound sensorineural hearing loss associated with biallelic variants in the OTOF genesource ↗
Drug Pipeline Intelligence
A88
Pipeline Score $55.8B
Pipeline ValueFair Value
Valuation Signal113
Drugs Scored2.8x
rNPV / MCap Top 99%
Large Pharma (rank 10 of 905)
Percentile RankRegeneron Pharmaceuticals, Inc. earns an A-grade pipeline score (88/100), with $55.8B risk-adjusted pipeline value, led by VEGF Trap-Eye in Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VEGF Trap-Eye Monoclonal antibody | Diabetes Mellitus | Phase 3 | NCT01331681 | 67% | $17.4B | COMPLETED | 406 | - | - | Mar 30, 2015 | - | Nov 27, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Libtayo | cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence | Phase 3 | 2025-10-17 | |||
Libtayo | cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence | Phase 3 | 2025-10-17 | |||
Libtayo | cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence | Phase 3 | 2025-10-17 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in REGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
REGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
REGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
REGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
REGN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
REGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
REGNregeneron to highlight progress across its metabolic disease ophthalmology and rare disease pipelines at ada and endo
regeneron to highlight progress across its metabolic disease ophthalmology and rare disease pipelines at ada and endo
Read more →REGNRegeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Regeneron Pharmaceuticals announced that the World Health Organization has recommended maftivimab, a component of the Inmazeb cocktail, for evaluation in clinical trials targeting the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda. This recommendation follows the WHO's declaration of the outbreak as a public health emergency. Regeneron is coordinating efforts with health authorities to facilitate the trials and has existing supplies of Inmazeb available for immediate use.
Read more →REGNLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Regeneron Pharmaceuticals announced positive results from the Phase 1/2 LINKER-AL2 trial of Lynozyfic (linvoseltamab) for systemic AL amyloidosis. All patients treated achieved hematologic complete response, with significant organ function improvements noted. The trial is ongoing, with the Phase 2 segment aimed at further validating these findings. The investigational treatment shows promise for patients with limited options.
Read more →REGNOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Regeneron Pharmaceuticals announced that the European Medicines Agency has accepted the Marketing Authorization Application for Otarmeni (lunsotogene parvec), a gene therapy for biallelic OTOF variant-associated hearing loss. This acceptance under Accelerated Assessment could lead to Otarmeni being the first gene therapy approved for this condition in the EU. The application is backed by data from the CHORD clinical trial, which demonstrated the therapy's potential effectiveness.
Read more →REGNregeneron announces strategic collaboration with parabilis medicines to advance novel antibody helicon conjugates across multiple therapeutic areas
regeneron announces strategic collaboration with parabilis medicines to advance novel antibody helicon conjugates across multiple therapeutic areas
Read more →REGNregeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma
regeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma
Read more →REGNnext generation of scientific leaders awarded more than 7 million at the 2026 regeneron international science and engineering fair
next generation of scientific leaders awarded more than 7 million at the 2026 regeneron international science and engineering fair
Read more →REGNRegeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
Regeneron Pharmaceuticals has been named to the Dow Jones Best-in-Class World Index for corporate sustainability for seven consecutive years. The company also earned a spot on the North America Index for six years. This recognition highlights Regeneron's commitment to corporate responsibility, including offering a new gene therapy for free in the U.S. and setting ambitious 2030 responsibility goals.
Read more →REGNDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
Regeneron Pharmaceuticals and Sanofi announced positive results from the REMODEL Phase 4 trial of Dupixent (dupilumab) for eosinophilic esophagitis (EoE). At week 24, patients treated with Dupixent exhibited significant improvements in esophageal distensibility and reductions in disease-related structural changes compared to placebo. These findings highlight Dupixent's effectiveness in managing EoE symptoms and improving patient quality of life.
Read more →REGNRegeneron Reports First Quarter 2026 Financial and Operating Results
Regeneron Pharmaceuticals reported a 19% increase in revenues for Q1 2026, reaching $3.6 billion. Key products like Dupixent and EYLEA HD saw significant sales growth and received new FDA approvals. The company also announced a $3 billion share repurchase program. However, EYLEA HD faced a 10% decrease in net sales and ongoing regulatory challenges.
Read more →REGNRegeneron Reports First Quarter 2026 Financial and Operating Results First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025 Dupixent global net sales (recorded by Sanofi) increa
Regeneron Pharmaceuticals reported a strong first quarter for 2026, with total revenues rising by 19% to $3.6 billion and Dupixent net sales increasing by 33%. The company highlighted significant growth in EYLEA HD sales by 52%, coupled with notable FDA approvals for several treatments. However, there was a 10% decline in GAAP net income, reflecting ongoing financial adjustments. The company's commitment to innovation continues with nearly 50 product candidates in clinical development, showcasing a robust pipeline and strategic collaborations.
Read more →REGNRegeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Regeneron Pharmaceuticals has announced a new agreement with the U.S. government to lower drug prices and provide its gene therapy, Otarmeni™, for free to American patients. The company will align Medicaid prices with those in other developed countries and allow direct purchase of Praluent® through TrumpRx.gov. This initiative aims to enhance access to innovative treatments while supporting domestic research and development.
Read more →REGNOtarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Regeneron Pharmaceuticals has received FDA approval for Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for severe-to-profound OTOF-related hearing loss. The approval is based on the CHORD trial, where 80% of participants showed significant hearing improvements. Regeneron will offer this therapy free of charge in the U.S., marking a significant advancement in treating genetic hearing loss.
Read more →REGNdupixent dupilumab approved in the u s as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria csu
dupixent dupilumab approved in the u s as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria csu
Read more →REGNcemdisiran dosed subcutaneously every 12 weeks demonstrates rapid deep and sustained disease control in generalized myasthenia gravis gmg phase 3 trial
cemdisiran dosed subcutaneously every 12 weeks demonstrates rapid deep and sustained disease control in generalized myasthenia gravis gmg phase 3 trial
Read more →REGNregeneron announces investor conference presentations
regeneron announces investor conference presentations
Read more →REGNDupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years. This approval is based on data from the LIBERTY-CUPID clinical trial program, demonstrating significant efficacy in reducing urticaria activity compared to placebo. Dupixent is now the first targeted therapy available for this age group in the EU.
Read more →REGNPress Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years. This marks a significant advancement as it is the first targeted therapy for this condition in young patients. The approval is based on positive results from clinical studies demonstrating Dupixent's efficacy and safety in reducing CSU symptoms. This development aims to improve the quality of life for children suffering from this debilitating skin condition.
Read more →REGNregeneron and telix announce strategic radiopharma collaboration
regeneron and telix announce strategic radiopharma collaboration
Read more →REGNTriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron Pharmaceuticals has entered a strategic collaboration with TriNetX to enhance its drug discovery and development capabilities. This partnership allows Regeneron to access a vast network of de-identified electronic health records from approximately 300 million patients. The collaboration aims to expand Regeneron's genomic and proteomic databases, facilitating advancements in digital health solutions and AI-driven research.
Read more →REGNeylea hd aflibercept approved by fda as first and only injectable anti vegf with dosing intervals up to 5 months for wet age related macular degeneration wamd and diabetic macular
eylea hd aflibercept approved by fda as first and only injectable anti vegf with dosing intervals up to 5 months for wet age related macular degeneration wamd and diabetic macular
Read more →REGNregeneron collaborates with trinetx to access de identified electronic health records of 300 million patients to drive research and product development in life sciences and digital
regeneron collaborates with trinetx to access de identified electronic health records of 300 million patients to drive research and product development in life sciences and digital
Read more →REGNRegeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
Regeneron Pharmaceuticals, Inc. will announce its first quarter 2026 financial results on April 29, 2026, before the markets open. A conference call and webcast will follow at 8:30 AM ET, allowing participants to engage directly. The company emphasizes its ongoing commitment to developing transformative medicines for serious diseases.
Read more →REGNDupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) has been approved in Japan for treating adults with moderate-to-severe bullous pemphigoid (BP). This approval is based on the results from the LIBERTY-BP-ADEPT Phase 2/3 trial, which showed that patients treated with Dupixent had over four times the rate of sustained disease remission compared to those receiving placebo. Dupixent is now the seventh approved indication for this drug in Japan.
Read more →REGNPress Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron's Dupixent has been approved in Japan as the first targeted therapy for adults with moderate-to-severe bullous pemphigoid. The approval is based on positive results from the pivotal LIBERTY-BP-ADEPT phase 2/3 study, which showed that Dupixent significantly improved disease remission rates compared to placebo. Despite some treatment-related adverse events, the drug's benefits in managing this rare skin condition are notable.
Read more →REGNregeneron science talent search 2026 recognizes america s top young scientists awarding more than 1 8 million to high school seniors for innovative research in computational mathem
regeneron science talent search 2026 recognizes america s top young scientists awarding more than 1 8 million to high school seniors for innovative research in computational mathem
Read more →REGNOlatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Regeneron Pharmaceuticals announced positive Phase 3 trial results for olatorepatide, a dual GLP-1/GIP receptor agonist, in Chinese patients with obesity. The trial showed significant weight loss, with participants losing up to 19% of their body weight over 48 weeks. The drug also exhibited a favorable tolerability profile, with lower rates of gastrointestinal adverse events compared to other treatments.
Read more →REGNregeneron announces investor conference presentation
regeneron announces investor conference presentation
Read more →REGNDupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
Dupixent (dupilumab) has received a positive recommendation from the European Medicines Agency's CHMP for the treatment of chronic spontaneous urticaria (CSU) in children aged 2 to 11 years. This would be the first targeted therapy for this condition in the EU. The recommendation is based on data from the LIBERTY-CUPID clinical trial program. A final decision from the European Commission is expected soon.
Read more →REGNPress Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
The European Medicines Agency's CHMP has recommended Dupixent for EU approval to treat chronic spontaneous urticaria in children aged two to 11 years. This decision is based on data from the LIBERTY-CUPID clinical studies. Dupixent is already approved for similar conditions in adults and adolescents, but its use in young children is still under evaluation.
Read more →REGNregeneron renews sponsorship of the regeneron science talent search through 2036 committing an additional 150 million to empower the next generation of science and technology leade
regeneron renews sponsorship of the regeneron science talent search through 2036 committing an additional 150 million to empower the next generation of science and technology leade
Read more →REGNDupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
The FDA has approved Dupixent (dupilumab) for treating allergic fungal rhinosinusitis (AFRS) in patients aged 6 and older. This decision is based on positive results from a Phase 3 trial, which demonstrated significant improvements in nasal symptoms and reduced reliance on surgery and corticosteroids. Dupixent is now recognized as a crucial treatment option for this chronic condition.
Read more →REGNPress Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
The FDA has approved Dupixent (dupilumab) for treating allergic fungal rhinosinusitis (AFRS) in patients aged 6 and older. This marks Dupixent as the first and only medication specifically for AFRS, which can cause severe nasal symptoms and complications. The approval is based on the LIBERTY-AFRS-AIMS phase 3 study, demonstrating significant improvements in sinus opacification and symptom relief. Dupixent's efficacy in reducing the need for surgery and corticosteroids highlights its potential to change the treatment landscape for this condition.
Read more →REGNgaretosmab biologics license application accepted for fda priority review for the treatment of fibrodysplasia ossificans progressiva fop
garetosmab biologics license application accepted for fda priority review for the treatment of fibrodysplasia ossificans progressiva fop
Read more →REGNRegeneron Announces Investor Conference Presentations - February 11, 2026
Regeneron Pharmaceuticals, Inc. has announced upcoming investor conference presentations scheduled for February 11, 2026. The sessions will be available via webcast on the company's website, with replays and transcripts archived for at least 30 days. Regeneron is recognized for its innovative approach in developing life-transforming medicines across various serious diseases.
Read more →REGNRegeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Regeneron Pharmaceuticals will present 36 abstracts at the 2026 AAAAI Annual Meeting, showcasing its expanding immunology portfolio. Notably, the company will introduce Phase 3 data for two investigational allergen-blocking antibodies targeting cat and birch allergies. Additionally, new insights on Dupixent's efficacy in treating various allergic and respiratory conditions will be shared, highlighting its potential to transform treatment paradigms.
Read more →REGNEYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
Regeneron Pharmaceuticals announced upcoming presentations at the Angiogenesis 2026 meeting, showcasing new clinical data for EYLEA HD (aflibercept) Injection 8 mg. The data highlights its efficacy and safety in treating serious retinal diseases, including the first every-two-month treatment option for retinal vein occlusion. Additionally, the ELARA trial results will support monthly treatment options for patients needing more frequent care.
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Regeneron Pharmaceuticals announced its financial results for Q4 and full year 2025, highlighting strong performance driven by blockbuster medicines like EYLEA HD and Dupixent. The company reported increased revenues and secured new approvals for its products. However, EYLEA faced challenges from competitive pressures and a decrease in market share. Looking forward, Regeneron aims to enhance shareholder value through strategic investments and share repurchases.
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024 full year 2025 revenues increased 1%
Regeneron Pharmaceuticals announced its financial results for Q4 and the full year 2025, showcasing a 3% increase in fourth-quarter revenues to $3.9 billion. The company noted significant growth in Dupixent sales, which rose by 34%, while EYLEA sales experienced a notable decline. Key product approvals were highlighted, including Libtayo for CSCC and Dupixent for chronic spontaneous urticaria. With ongoing investments in innovation and a comprehensive pipeline, Regeneron remains focused on enhancing shareholder value and achieving sustainable growth in the coming years.
Read more →REGNNation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
The Regeneron Science Talent Search 2026 has announced its top 40 finalists, showcasing exceptional high school scientists. This prestigious competition, celebrating its 85th year, highlights the importance of nurturing young talent in science. Regeneron, a key sponsor, emphasizes its commitment to supporting STEM education and innovation through significant financial awards.
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
Regeneron Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on January 30, 2026. A conference call and webcast will follow at 8:30 AM ET. Participants can access the call via the company's website or telephone registration. Regeneron is recognized for its innovative medicines and strong pipeline.
Read more →REGNregeneron to report fourth quarter and full year 2025 financial and operating results and host conference call and webcast on january 30 2026
regeneron to report fourth quarter and full year 2025 financial and operating results and host conference call and webcast on january 30 2026
Read more →REGNJ a n u a r y 1 2 , 2 0 2 6 J.P. Morgan Healthcare Conference This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. 2 J.P. Morgan Healt
Regeneron Pharmaceuticals is set to advance its pipeline with several key milestones expected in 2026, including Phase 3 trials for R7508 and R9933 in anticoagulation therapies. Prominent drug candidates such as cemdisiran and Dupixent are anticipated to reach critical FDA decision points in the coming year. The company is also exploring innovative combination therapies for obesity, which could offer significant efficacy enhancements. Despite the optimistic developments, the article cautions about the variability associated with investigational therapies and the ongoing challenges related to bleeding risks in anticoagulation treatments.
Read more →REGNdupixent dupilumab approved in japan for children aged 6 to 11 years with bronchial asthma
dupixent dupilumab approved in japan for children aged 6 to 11 years with bronchial asthma
Read more →REGNregeneron announces presentation at the 44th annual j p morgan healthcare conference
regeneron announces presentation at the 44th annual j p morgan healthcare conference
Read more →REGNLynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
Regeneron Pharmaceuticals announced promising results from the Phase 1/2 LINKER-MM4 trial of Lynozyfic (linvoseltamab) in newly diagnosed multiple myeloma (NDMM). The trial demonstrated over 70% VGPR+ rates and 95% of evaluable patients achieving minimal residual disease negativity. These findings suggest Lynozyfic could serve as a foundational treatment for NDMM, simplifying current complex regimens. The company plans to further discuss these results in an upcoming investor event.
Read more →REGNRegeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Regeneron Pharmaceuticals and Tessera Therapeutics have announced a global collaboration to develop TSRA-196, an investigational gene editing therapy for alpha-1 antitrypsin deficiency (AATD). This partnership combines Regeneron's genetic capabilities with Tessera's innovative Gene Writing technology. Tessera plans to file an Investigational New Drug application with the FDA by year-end, aiming to initiate clinical trials soon.
Read more →REGNDupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond adequately to antihistamines. This marks the first new targeted therapy for CSU in over ten years. Phase 3 trials showed that Dupixent significantly reduced symptoms of itch and hives, providing a new treatment option for patients suffering from this debilitating condition.
Read more →REGNEYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
Regeneron Pharmaceuticals announced FDA approval for EYLEA HD (aflibercept) Injection 8 mg, the first treatment for macular edema following retinal vein occlusion (RVO) with flexible dosing options. Patients can now receive treatment every 8 weeks after an initial monthly period. The approval is based on the Phase 3 QUASAR trial, demonstrating comparable efficacy to existing therapies. EYLEA HD aims to enhance patient care with fewer injections and tailored dosing schedules.
Read more →REGNLibtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
Regeneron Pharmaceuticals announced that the European Commission has approved Libtayo (cemiplimab) as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. This approval is based on the Phase 3 C-POST trial results, which showed a 68% reduction in the risk of recurrence or death. Libtayo is expected to change the treatment landscape for earlier-stage CSCC patients.
Read more →REGNRegeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
Regeneron Pharmaceuticals announced new data from its hematology portfolio at the ASH 2025 Annual Meeting. Key presentations included updates on Lynozyfic for multiple myeloma and odronextamab for lymphoma treatments. The company also highlighted its innovative approaches to address unmet needs in blood cancers and disorders. A virtual investor event is scheduled to discuss the multiple myeloma program further.
Read more →REGNPhase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
Regeneron Pharmaceuticals has announced positive Phase 2 trial results for two novel factor XI antibodies, REGN7508Cat and REGN9933A2, aimed at preventing blood clots in patients undergoing total knee replacement. The trials showed distinct anti-clotting effects with no clinically relevant bleeding, supporting the potential for tailored anticoagulant therapies. Phase 3 trials are now underway as part of a broader factor XI program.
Read more →REGNDupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) successfully met all primary and secondary endpoints in a pivotal Phase 3 trial for allergic fungal rhinosinusitis (AFRS). The FDA has accepted the supplemental Biologics License Application for priority review, with a target action date of February 28, 2026. If approved, Dupixent will be the first treatment specifically indicated for AFRS, marking its ninth FDA-approved indication.
Read more →REGNRegeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. will host webcasts featuring management presentations, accessible via their website. The sessions will be archived for 30 days. Regeneron is recognized for its innovative medicines targeting serious diseases, leveraging advanced technologies for drug development.
Read more →REGNDupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
Regeneron Pharmaceuticals' Dupixent (dupilumab) has been awarded the 2025 Prix Galien USA for 'Best Biotechnology Product.' This recognition highlights its groundbreaking science and impact on various allergic and atopic conditions. Dupixent, the first therapy targeting the IL-4 and IL-13 pathways, has shown significant clinical benefits across multiple indications, with over 1 million patients currently treated worldwide.
Read more →REGNRegeneron Reports Third Quarter 2025 Financial and Operating Results
Regeneron Pharmaceuticals reported strong financial results for Q3 2025, highlighting new FDA approvals for Libtayo, Evkeeza, and Lynozyfic. The company emphasized its commitment to innovation with nearly $5 billion invested in R&D. Despite competitive pressures affecting EYLEA sales, Regeneron continues to show growth in its product portfolio and shareholder returns.
Read more →REGNRegeneron Reports Third Quarter 2025 Financial and Operating Results Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent global net sales (recorded by Sanofi) increa
Regeneron Pharmaceuticals reported a 1% increase in total revenues for Q3 2025, totaling $3.75 billion, with Dupixent's global sales rising sharply. The company received FDA approval for Libtayo as the first immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma. Despite positive developments, EYLEA's sales declined significantly, and the FDA issued a Complete Response Letter regarding some product applications due to manufacturing issues. Overall, Regeneron's strong financial performance highlights its ongoing commitment to innovation and shareholder value.
Read more →REGNLibtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Regeneron Pharmaceuticals announced that the CHMP has recommended Libtayo (cemiplimab) for EU approval as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence. This recommendation is based on positive results from the Phase 3 C-POST trial, which demonstrated a 68% reduction in the risk of disease recurrence. The European Commission's final decision is anticipated soon.
Read more →REGNRegeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
Regeneron Pharmaceuticals announced it will present new data from its oncology pipeline at the ESMO 2025 Meeting. Key highlights include Phase 3 data on Libtayo, an immunotherapy for cutaneous squamous cell carcinoma. The data supports a new every 6-week dosing regimen, enhancing treatment options for patients at high risk of recurrence.
Read more →REGNDB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
Regeneron's investigational gene therapy DB-OTO has shown promising results in treating profound genetic hearing loss, with 11 out of 12 participants experiencing significant hearing improvements. Notably, three participants achieved normal hearing levels, and speech assessments indicated substantial progress. The therapy is set for U.S. regulatory submission later this year, following positive outcomes from the pivotal CHORD trial.
Read more →REGNLibtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Regeneron Pharmaceuticals has received FDA approval for Libtayo (cemiplimab-rwlc) as the first immunotherapy for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The approval is based on the Phase 3 C-POST trial, which demonstrated a 68% reduction in disease recurrence risk. This approval is expected to change treatment paradigms for earlier-stage CSCC patients. Regeneron is also pursuing additional regulatory applications in the EU.
Read more →REGNregeneron to report third quarter 2025 financial and operating results and host conference call and webcast on october 28 2025
regeneron to report third quarter 2025 financial and operating results and host conference call and webcast on october 28 2025
Read more →REGNevkeeza evinacumab dgnb angptl3 antibody approved in the u s for children as young as 1 year old with ultra rare form of high cholesterol
evkeeza evinacumab dgnb angptl3 antibody approved in the u s for children as young as 1 year old with ultra rare form of high cholesterol
Read more →REGNdupixent dupilumab to treat chronic spontaneous urticaria csu advances in eu with positive chmp opinion
dupixent dupilumab to treat chronic spontaneous urticaria csu advances in eu with positive chmp opinion
Read more →REGNregeneron donates ebola treatment for use in countries most at risk of outbreaks
regeneron donates ebola treatment for use in countries most at risk of outbreaks
Read more →REGNregeneron announces positive phase 3 trial in adults with ultra rare genetic disorder fibrodysplasia ossificans progressiva fop demonstrating that garetosmab prevents greater than
regeneron announces positive phase 3 trial in adults with ultra rare genetic disorder fibrodysplasia ossificans progressiva fop demonstrating that garetosmab prevents greater than
Read more →REGNresults from phase 2 courage trial demonstrating potential to improve quality of glp 1 receptor agonist induced weight loss by preserving lean mass presented at easd
results from phase 2 courage trial demonstrating potential to improve quality of glp 1 receptor agonist induced weight loss by preserving lean mass presented at easd
Read more →REGNlibtayo cemiplimab plus chemotherapy results at five years reinforce significant and durable improvements in survival outcomes for advanced non small cell lung cancer
libtayo cemiplimab plus chemotherapy results at five years reinforce significant and durable improvements in survival outcomes for advanced non small cell lung cancer
Read more →REGNregeneron advances allergy pipeline with two positive phase 3 trials evaluating first in class antibody blockers of cat and birch allergies
regeneron advances allergy pipeline with two positive phase 3 trials evaluating first in class antibody blockers of cat and birch allergies
Read more →REGNregeneron announces updated presentation time for upcoming investor conference
regeneron announces updated presentation time for upcoming investor conference
Read more →REGNregeneron announces positive results from phase 3 trial in generalized myasthenia gravis
regeneron announces positive results from phase 3 trial in generalized myasthenia gravis
Read more →REGNeylea hd aflibercept injection 8 mg applications for expanded u s label and prefilled syringe receive fda review period extension
eylea hd aflibercept injection 8 mg applications for expanded u s label and prefilled syringe receive fda review period extension
Read more →REGNregeneron reports second quarter 2025 financial and operating results
regeneron reports second quarter 2025 financial and operating results
Read more →REGNRegeneron Reports Second Quarter 2025 Financial and Operating Results Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024 Dupixent global net sales (recorded by Sanofi) inc
Regeneron reported its Q2 2025 financial results, highlighting a 4% increase in revenues to $3.68 billion. Key product Dupixent experienced a robust 22% rise in global net sales, and recent FDA approvals for Lynozyfic and Dupixent mark significant advancements in their treatment offerings. However, Regeneron also noted a drop in EYLEA HD U.S. sales and anticipated delays in certain regulatory approvals. Overall, the company remains optimistic about its diverse pipeline and strong business performance despite some setbacks.
Read more →REGNregeneron announces the 2025 winners of the regeneron prize for creative innovation
regeneron announces the 2025 winners of the regeneron prize for creative innovation
Read more →REGNlynozyfic linvoseltamab gcpt receives fda accelerated approval for treatment of relapsed or refractory multiple myeloma
lynozyfic linvoseltamab gcpt receives fda accelerated approval for treatment of relapsed or refractory multiple myeloma
Read more →REGNregeneron to report second quarter 2025 financial and operating results and host conference call and webcast on august 1 2025
regeneron to report second quarter 2025 financial and operating results and host conference call and webcast on august 1 2025
Read more →REGNregeneron announces first of its kind donation matching program with independent charitable patient assistance organization
regeneron announces first of its kind donation matching program with independent charitable patient assistance organization
Read more →REGNdupixent dupilumab approved in the u s as the only targeted medicine to treat patients with bullous pemphigoid bp
dupixent dupilumab approved in the u s as the only targeted medicine to treat patients with bullous pemphigoid bp
Read more →REGNdupixent dupilumab demonstrated superiority over xolair omalizumab in chronic rhinosinusitis with nasal polyps crswnp in patients with coexisting asthma in first ever presented pha
dupixent dupilumab demonstrated superiority over xolair omalizumab in chronic rhinosinusitis with nasal polyps crswnp in patients with coexisting asthma in first ever presented pha
Read more →REGNdupixent dupilumab data at revolutionizing atopic dermatitis rad conference reinforce use in atopic dermatitis patients with skin of color
dupixent dupilumab data at revolutionizing atopic dermatitis rad conference reinforce use in atopic dermatitis patients with skin of color
Read more →REGNinterim results from ongoing phase 2 courage trial confirm potential to improve the quality of semaglutide glp 1 receptor agonist induced weight loss by preserving lean mass
interim results from ongoing phase 2 courage trial confirm potential to improve the quality of semaglutide glp 1 receptor agonist induced weight loss by preserving lean mass
Read more →REGNregeneron expands clinical stage obesity portfolio with strategic in licensing of novel dual glp 1 gip receptor agonist
regeneron expands clinical stage obesity portfolio with strategic in licensing of novel dual glp 1 gip receptor agonist
Read more →REGNlibtayo cemiplimab phase 3 data in the adjuvant treatment of post surgical high risk cutaneous squamous cell carcinoma cscc have potential to be practice changing
libtayo cemiplimab phase 3 data in the adjuvant treatment of post surgical high risk cutaneous squamous cell carcinoma cscc have potential to be practice changing
Read more →REGNitepekimab met primary endpoint in one of two chronic obstructive pulmonary disease copd phase 3 trials
itepekimab met primary endpoint in one of two chronic obstructive pulmonary disease copd phase 3 trials
Read more →REGNlinvoseltamab in combination with carfilzomib or bortezomib shows promising initial results in earlier lines of treatment for relapsed refractory multiple myeloma
linvoseltamab in combination with carfilzomib or bortezomib shows promising initial results in earlier lines of treatment for relapsed refractory multiple myeloma
Read more →REGNregeneron enters into asset purchase agreement to acquire 23andme for 256 million plans to maintain consumer genetics business and advance shared goals of improving human health an
regeneron enters into asset purchase agreement to acquire 23andme for 256 million plans to maintain consumer genetics business and advance shared goals of improving human health an
Read more →REGN75th annual regeneron international science and engineering fair awards teen scientists from around the world more than 9 million in 2025 competition
75th annual regeneron international science and engineering fair awards teen scientists from around the world more than 9 million in 2025 competition
Read more →REGNregeneron prevails over amgen in antitrust pcsk9 lawsuit protecting biotech innovation and patient access to life saving treatments
regeneron prevails over amgen in antitrust pcsk9 lawsuit protecting biotech innovation and patient access to life saving treatments
Read more →REGNdupixent dupilumab data presented at ats reinforce impact of targeting key type 2 inflammation drivers to improve outcomes for chronic respiratory diseases
dupixent dupilumab data presented at ats reinforce impact of targeting key type 2 inflammation drivers to improve outcomes for chronic respiratory diseases
Read more →REGNregeneron to highlight advances at asco with phase 3 adjuvant libtayo cemiplimab cscc updates and promising early blood cancer data with linvoseltamab combination
regeneron to highlight advances at asco with phase 3 adjuvant libtayo cemiplimab cscc updates and promising early blood cancer data with linvoseltamab combination
Read more →REGNregeneron reports first quarter 2025 financial and operating results
regeneron reports first quarter 2025 financial and operating results
Read more →REGNRegeneron Reports First Quarter 2025 Financial and Operating Results First quarter 2025 revenues of $3.0 billion GAAP diluted EPS of $7.27 and non-GAAP diluted EPS (a) of $8.22 First quarter 2025 Dupixent g
Regeneron Pharmaceuticals announced its financial results for Q1 2025, reporting revenues of $3.0 billion and a GAAP diluted EPS of $7.27. Notably, Dupixent’s global net sales reached $3.67 billion, a 19% increase from the previous year. The company is advancing its clinical pipeline, with new approvals for Dupixent in the U.S. and Japan and several ongoing studies. However, total revenues declined by 4% year-over-year, and the FDA issued a Complete Response Letter regarding the EYLEA HD application, prompting further evaluation.
Read more →REGNlynozyfic linvoseltamab approved in the european union for the treatment of relapsed refractory multiple myeloma
lynozyfic linvoseltamab approved in the european union for the treatment of relapsed refractory multiple myeloma
Read more →REGNeylea hd aflibercept injection 8 mg presentations at arvo reinforce continued safety and efficacy and highlight early real world outcomes for patients with serious retinal disease
eylea hd aflibercept injection 8 mg presentations at arvo reinforce continued safety and efficacy and highlight early real world outcomes for patients with serious retinal disease
Read more →REGNregeneron announces new investment in manufacturing of its industry leading biologic medicines
regeneron announces new investment in manufacturing of its industry leading biologic medicines
Read more →REGNregeneron provides update on eylea hd aflibercept injection 8 mg supplemental biologics license application
regeneron provides update on eylea hd aflibercept injection 8 mg supplemental biologics license application
Read more →REGNdupixent dupilumab approved in the u s as the first new targeted therapy in over a decade for chronic spontaneous urticaria csu
dupixent dupilumab approved in the u s as the first new targeted therapy in over a decade for chronic spontaneous urticaria csu
Read more →REGNeylea hd aflibercept injection 8 mg sbla accepted for fda priority review for both the treatment of macular edema following retinal vein occlusion rvo and for monthly dosing in app
eylea hd aflibercept injection 8 mg sbla accepted for fda priority review for both the treatment of macular edema following retinal vein occlusion rvo and for monthly dosing in app
Read more →REGNdupixent dupilumab approved as the first ever biologic medicine in japan for patients with chronic obstructive pulmonary disease copd
dupixent dupilumab approved as the first ever biologic medicine in japan for patients with chronic obstructive pulmonary disease copd
Read more →REGNregeneron to report first quarter 2025 financial and operating results and host conference call and webcast on april 29 2025
regeneron to report first quarter 2025 financial and operating results and host conference call and webcast on april 29 2025
Read more →REGNregeneron science talent search 2025 awards more than 1 8 million to high school seniors for innovative scientific research on classifying objects in space treating a rare muscle d
regeneron science talent search 2025 awards more than 1 8 million to high school seniors for innovative scientific research on classifying objects in space treating a rare muscle d
Read more →REGNdupixent dupilumab late breaking positive pivotal data in bullous pemphigoid presented at aad
dupixent dupilumab late breaking positive pivotal data in bullous pemphigoid presented at aad
Read more →REGNlinvoseltamab recommended for eu approval by the chmp to treat relapsed refractory multiple myeloma
linvoseltamab recommended for eu approval by the chmp to treat relapsed refractory multiple myeloma
Read more →REGNodronextamab bla accepted for fda review for the treatment of relapsed refractory follicular lymphoma
odronextamab bla accepted for fda review for the treatment of relapsed refractory follicular lymphoma
Read more →REGNlatest db oto results demonstrate clinically meaningful hearing improvements in nearly all children with profound genetic hearing loss in chord trial
latest db oto results demonstrate clinically meaningful hearing improvements in nearly all children with profound genetic hearing loss in chord trial
Read more →REGNdupixent dupilumab sbla accepted for fda priority review for the targeted treatment of bullous pemphigoid bp
dupixent dupilumab sbla accepted for fda priority review for the targeted treatment of bullous pemphigoid bp
Read more →REGNlinvoseltamab bla accepted for fda review for the treatment of relapsed refractory multiple myeloma
linvoseltamab bla accepted for fda review for the treatment of relapsed refractory multiple myeloma
Read more →REGNthree year results for eylea hd aflibercept injection 8 mg in patients with wet age related macular degeneration demonstrate continued durable vision gains and anatomic improvement
three year results for eylea hd aflibercept injection 8 mg in patients with wet age related macular degeneration demonstrate continued durable vision gains and anatomic improvement
Read more →REGNeylea hd aflibercept injection 8 mg positive phase 3 results in patients with macular edema following retinal vein occlusion presented at angiogenesis meeting
eylea hd aflibercept injection 8 mg positive phase 3 results in patients with macular edema following retinal vein occlusion presented at angiogenesis meeting
Read more →REGNregeneron reports fourth quarter and full year 2024 financial and operating results initiates quarterly dividend and increases total share repurchase capacity to 4 5 billion
regeneron reports fourth quarter and full year 2024 financial and operating results initiates quarterly dividend and increases total share repurchase capacity to 4 5 billion
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion Fourth quarter 2024 revenues in
Regeneron Pharmaceuticals reported strong financial results for Q4 and FY 2024, with revenues up 10% and net sales for key products like Dupixent and Libtayo showing significant growth. The company announced the initiation of a quarterly cash dividend program and increased its share repurchase capacity to $4.5 billion, reflecting confidence in its financial health. However, there was a notable 21% decrease in GAAP net income for the fourth quarter compared to the previous year. Regeneron continues to advance its product pipeline with multiple regulatory submissions and positive clinical trial outcomes.
Read more →REGNamerica s top 40 high school scientists to compete for 1 8 million in awards at prestigious regeneron science talent search
america s top 40 high school scientists to compete for 1 8 million in awards at prestigious regeneron science talent search
Read more →REGNregeneron collaborates with truveta and leading american health systems to massively extend its dna sequence linked healthcare database to further advance scientific innovation and
regeneron collaborates with truveta and leading american health systems to massively extend its dna sequence linked healthcare database to further advance scientific innovation and
Read more →REGNadjuvant libtayo cemiplimab significantly improves disease free survival dfs after surgery in high risk cutaneous squamous cell carcinoma cscc in phase 3 trial
adjuvant libtayo cemiplimab significantly improves disease free survival dfs after surgery in high risk cutaneous squamous cell carcinoma cscc in phase 3 trial
Read more →REGNregeneron provides business updates and highlights from broad clinical pipeline at the 43rd annual j p morgan healthcare conference
regeneron provides business updates and highlights from broad clinical pipeline at the 43rd annual j p morgan healthcare conference
Read more →REGNRegeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43 rd Annual J.P. Morgan Healthcare Conference Dupixent is now used to treat over a million patients globally, with con
Regeneron Pharmaceuticals provided updates on its clinical pipeline and business performance during the 43rd Annual J.P. Morgan Healthcare Conference. Dupixent has gained widespread usage, reaching over a million patients globally, while EYLEA remains a leader in the anti-VEGF category with $6 billion in sales. Libtayo achieved over $1 billion in annual sales, marking a significant milestone in the immunotherapy market. Furthermore, Regeneron is expanding its DNA-linked healthcare database to enhance its drug discovery potential, emphasizing continuous investment in R&D.
Read more →REGNregeneron to report fourth quarter and full year 2024 financial and operating results and host conference call and webcast on february 4 2025
regeneron to report fourth quarter and full year 2024 financial and operating results and host conference call and webcast on february 4 2025
Read more →REGNregeneron to advance two factor xi antibodies into a broad phase 3 program following positive phase 2 proof of concept results
regeneron to advance two factor xi antibodies into a broad phase 3 program following positive phase 2 proof of concept results
Read more →REGNregeneron announces presentation at the 43rd annual j p morgan healthcare conference
regeneron announces presentation at the 43rd annual j p morgan healthcare conference
Read more →REGNeylea hd aflibercept injection 8 mg phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vei
eylea hd aflibercept injection 8 mg phase 3 trial meets primary endpoint showing improved vision with extended dosing intervals in patients with macular edema following retinal vei
Read more →REGNregeneron named to dow jones sustainability world index for sixth consecutive year
regeneron named to dow jones sustainability world index for sixth consecutive year
Read more →REGNodronextamab ash presentations underscore impressive potential in earlier lines of treatment and additional types of lymphoma
odronextamab ash presentations underscore impressive potential in earlier lines of treatment and additional types of lymphoma
Read more →REGNnovel combination of pozelimab and cemdisiran poze cemdi achieved greater control of intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria compared to ravuli
novel combination of pozelimab and cemdisiran poze cemdi achieved greater control of intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria compared to ravuli
Read more →REGNdupixent dupilumab sbla accepted for fda review for the treatment of chronic spontaneous urticaria csu
dupixent dupilumab sbla accepted for fda review for the treatment of chronic spontaneous urticaria csu
Read more →REGNregeneron to highlight pioneering pipeline progress across multiple modalities spanning 10 types of blood cancers and disorders at ash
regeneron to highlight pioneering pipeline progress across multiple modalities spanning 10 types of blood cancers and disorders at ash
Read more →REGNdupixent dupilumab approved in the european union as the first and only medicine for young children with eosinophilic esophagitis
dupixent dupilumab approved in the european union as the first and only medicine for young children with eosinophilic esophagitis
Read more →REGNregeneron reports third quarter 2024 financial and operating results
regeneron reports third quarter 2024 financial and operating results
Read more →REGNRegeneron Reports Third Quarter 2024 Financial and Operating Results Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 Third quarter 2024 Dupixent global net sales (record
Regeneron Pharmaceuticals reported a strong third quarter in 2024, with revenues reaching $3.72 billion thanks to a significant growth in Dupixent sales. The FDA approved Dupixent for new indications, marking it the first biologic treatment for certain chronic obstructive pulmonary disease patients. The company also noted an 11% increase in total revenue and a robust pipeline with around 40 product candidates in development. However, there were challenges with EYLEA’s sales and recent regulatory setbacks regarding linvoseltamab.
Read more →REGNdupixent dupilumab late breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai
dupixent dupilumab late breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai
Read more →REGNthree year results for eylea hd aflibercept injection 8 mg demonstrate continued durable vision gains and anatomic improvements with extended dosing intervals in patients with diab
three year results for eylea hd aflibercept injection 8 mg demonstrate continued durable vision gains and anatomic improvements with extended dosing intervals in patients with diab
Read more →REGNdupixent dupilumab approved in the u s as the first ever biologic medicine for patients with copd
dupixent dupilumab approved in the u s as the first ever biologic medicine for patients with copd
Read more →REGNdupixent dupilumab approved in china as the first ever biologic medicine for patients with chronic obstructive pulmonary disease copd
dupixent dupilumab approved in china as the first ever biologic medicine for patients with chronic obstructive pulmonary disease copd
Read more →REGNregeneron to report third quarter 2024 financial and operating results and host conference call and webcast on october 31 2024
regeneron to report third quarter 2024 financial and operating results and host conference call and webcast on october 31 2024
Read more →REGNdupixent dupilumab recommended for eu approval by the chmp to treat eosinophilic esophagitis eoe in children as young as 1 year old
dupixent dupilumab recommended for eu approval by the chmp to treat eosinophilic esophagitis eoe in children as young as 1 year old
Read more →REGNdupixent dupilumab approved in the u s as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps crswnp
dupixent dupilumab approved in the u s as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps crswnp
Read more →REGNeylea hd aflibercept injection 8 mg data at euretina reinforce long term durability sustained fluid control and safety profile
eylea hd aflibercept injection 8 mg data at euretina reinforce long term durability sustained fluid control and safety profile
Read more →REGNdupixent dupilumab phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria csu
dupixent dupilumab phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria csu
Read more →REGNdupixent dupilumab is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid bp positive pivotal trial
dupixent dupilumab is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid bp positive pivotal trial
Read more →REGNlibtayo cemiplimab demonstrates durable survival benefit at five years in advanced non small cell lung cancer
libtayo cemiplimab demonstrates durable survival benefit at five years in advanced non small cell lung cancer
Read more →REGNregeneron to highlight progress across its differentiated oncology portfolio and pipeline at wclc and esmo
regeneron to highlight progress across its differentiated oncology portfolio and pipeline at wclc and esmo
Read more →REGNordspono odronextamab approved in the european union for the treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
ordspono odronextamab approved in the european union for the treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
Read more →REGNlatest dupixent dupilumab and itepekimab data at ers highlight scientific innovation and leadership in respiratory diseases
latest dupixent dupilumab and itepekimab data at ers highlight scientific innovation and leadership in respiratory diseases
Read more →REGNregeneron provides update on biologics license application for linvoseltamab
regeneron provides update on biologics license application for linvoseltamab
Read more →REGNregeneron announces investor conference presentations and oncology investor webcast
regeneron announces investor conference presentations and oncology investor webcast
Read more →REGNregeneron reports second quarter 2024 financial and operating results
regeneron reports second quarter 2024 financial and operating results
Read more →REGNRegeneron Reports Second Quarter 2024 Financial and Operating Results Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023 Second quarter 2024 Dupixent global net sales (re
Regeneron Pharmaceuticals, Inc. revealed its financial results for the second quarter of 2024, showcasing a 12% increase in total revenues to $3.55 billion compared to the previous year. Key products, including Dupixent and Libtayo, saw significant growth, particularly with Dupixent's sales rising 27% to $3.56 billion. Notably, Dupixent received its first European regulatory approval for treating chronic obstructive pulmonary disease (COPD). Additionally, the company is committed to advancing its clinical pipeline with several important studies expected in the coming months.
Read more →REGNregeneron announces the 2024 winners of the regeneron prize for creative innovation
regeneron announces the 2024 winners of the regeneron prize for creative innovation
Read more →REGNdupixent dupilumab approved in the european union as the first ever targeted therapy for patients with copd
dupixent dupilumab approved in the european union as the first ever targeted therapy for patients with copd
Read more →REGNodronextamab recommended for eu approval by the chmp to treat relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
odronextamab recommended for eu approval by the chmp to treat relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
Read more →REGNregeneron to report second quarter 2024 financial and operating results and host conference call and webcast on august 1 2024
regeneron to report second quarter 2024 financial and operating results and host conference call and webcast on august 1 2024
Read more →REGNdupixent dupilumab positive phase 3 data in children 1 to 11 years of age with eosinophilic esophagitis published in the new england journal of medicine
dupixent dupilumab positive phase 3 data in children 1 to 11 years of age with eosinophilic esophagitis published in the new england journal of medicine
Read more →REGNupdated linvoseltamab data showcase continued deepening of responses in patients with heavily pre treated multiple myeloma
updated linvoseltamab data showcase continued deepening of responses in patients with heavily pre treated multiple myeloma
Read more →REGNkevzara sarilumab approved by fda for the treatment of active polyarticular juvenile idiopathic arthritis pjia
kevzara sarilumab approved by fda for the treatment of active polyarticular juvenile idiopathic arthritis pjia
Read more →REGNdupixent dupilumab recommended for eu approval by the chmp to treat patients with copd
dupixent dupilumab recommended for eu approval by the chmp to treat patients with copd
Read more →REGNupdate on fda priority review of dupixent dupilumab for the treatment of copd patients with type 2 inflammation
update on fda priority review of dupixent dupilumab for the treatment of copd patients with type 2 inflammation
Read more →REGNpromising anti tumor activity of novel costimulatory bispecific antibody regn7075 egfrxcd28 in combination with libtayo cemiplimab to be reported at asco
promising anti tumor activity of novel costimulatory bispecific antibody regn7075 egfrxcd28 in combination with libtayo cemiplimab to be reported at asco
Read more →REGNdupixent dupilumab late breaking data from notus confirmatory phase 3 copd trial presented at ats and published in the new england journal of medicine
dupixent dupilumab late breaking data from notus confirmatory phase 3 copd trial presented at ats and published in the new england journal of medicine
Read more →REGNmore than 9 million awarded to high school scientists and engineers at the regeneron international science and engineering fair 2024
more than 9 million awarded to high school scientists and engineers at the regeneron international science and engineering fair 2024
Read more →REGNdupixent dupilumab sbla accepted for fda priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis crswnp
dupixent dupilumab sbla accepted for fda priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis crswnp
Read more →REGNlatest db oto results show dramatically improved hearing to normal levels in a child with profound genetic deafness within 24 weeks and initial hearing improvements in a second chi
latest db oto results show dramatically improved hearing to normal levels in a child with profound genetic deafness within 24 weeks and initial hearing improvements in a second chi
Read more →REGNregeneron reports first quarter 2024 financial and operating results
regeneron reports first quarter 2024 financial and operating results
Read more →REGNRegeneron Reports First Quarter 2024 Financial and Operating Results First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023 excluding Ronapreve TM(a)(b) , revenues increased 7%
Regeneron Pharmaceuticals reported its financial results for the first quarter of 2024, revealing a 1% decrease in total revenues to $3.15 billion. Despite this decline, revenues excluding Ronapreve showed a 7% increase, bolstered by strong sales of Dupixent and Libtayo. The company also announced a new $3.0 billion share repurchase program, demonstrating confidence in its financial future. The progress of its clinical pipeline, including multiple regulatory applications, particularly for Dupixent and linvoseltamab, was highlighted.
Read more →REGNeylea hd aflibercept injection 8 mg presentations at arvo reinforce sustained and clinically meaningful outcomes in serious retinal diseases
eylea hd aflibercept injection 8 mg presentations at arvo reinforce sustained and clinically meaningful outcomes in serious retinal diseases
Read more →REGNregeneron and mammoth biosciences collaborate to pursue next generation crispr based gene editing for multiple diseases
regeneron and mammoth biosciences collaborate to pursue next generation crispr based gene editing for multiple diseases
Read more →REGNregeneron to showcase progress in advancing novel investigational treatment approaches for a broad range of solid tumors and blood cancers at asco
regeneron to showcase progress in advancing novel investigational treatment approaches for a broad range of solid tumors and blood cancers at asco
Read more →REGNregeneron to highlight advances in genetic medicine research at american society of gene and cell therapy asgct
regeneron to highlight advances in genetic medicine research at american society of gene and cell therapy asgct
Read more →REGNlinvoseltamab pivotal data presented at aacr reinforce high response rate that deepens over time in patients with heavily pre treated multiple myeloma
linvoseltamab pivotal data presented at aacr reinforce high response rate that deepens over time in patients with heavily pre treated multiple myeloma
Read more →REGNregeneron to report first quarter 2024 financial and operating results and host conference call and webcast on may 2 2024
regeneron to report first quarter 2024 financial and operating results and host conference call and webcast on may 2 2024
Read more →REGNregeneron provides update on biologics license application for odronextamab
regeneron provides update on biologics license application for odronextamab
Read more →REGNhigh school seniors win 1 8 million at regeneron science talent search 2024 for innovative scientific research on artificial intelligence cancer metabolism and mathematical optimiz
high school seniors win 1 8 million at regeneron science talent search 2024 for innovative scientific research on artificial intelligence cancer metabolism and mathematical optimiz
Read more →REGNpraluent alirocumab injection receives fda approval to treat children with genetic form of high cholesterol
praluent alirocumab injection receives fda approval to treat children with genetic form of high cholesterol
Read more →REGNeylea hd aflibercept injection 8 mg pivotal data in wet age related macular degeneration wamd and diabetic macular edema dme published in the lancet
eylea hd aflibercept injection 8 mg pivotal data in wet age related macular degeneration wamd and diabetic macular edema dme published in the lancet
Read more →REGNdupixent dupilumab sbla accepted for fda priority review for treatment of copd with type 2 inflammation
dupixent dupilumab sbla accepted for fda priority review for treatment of copd with type 2 inflammation
Read more →REGNlinvoseltamab bla for treatment of relapsed refractory multiple myeloma accepted for fda priority review
linvoseltamab bla for treatment of relapsed refractory multiple myeloma accepted for fda priority review
Read more →REGNjapan first in the world to approve dupixent dupilumab for chronic spontaneous urticaria csu
japan first in the world to approve dupixent dupilumab for chronic spontaneous urticaria csu
Read more →REGNregeneron reports fourth quarter and full year 2023 financial and operating results
regeneron reports fourth quarter and full year 2023 financial and operating results
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022 excluding Ronapreve TM(a)(b) , reven
Regeneron Pharmaceuticals, Inc. reported its fourth quarter and full year 2023 financial results, showcasing a 1% increase in revenues to $3.43 billion for Q4 and an 8% increase to $13.12 billion for the entire year. Notable growth was observed in Dupixent and Libtayo, with respective increases in global net sales of 31% and 44%. The company also highlighted advancements in its drug pipeline, with significant progress on Dupixent submissions for COPD and linvoseltamab for multiple myeloma. Despite these positives, GAAP net income saw a small decline during the fourth quarter compared to the previous year.
Read more →REGNlinvoseltamab receives ema filing acceptance for treatment of relapsed refractory multiple myeloma
linvoseltamab receives ema filing acceptance for treatment of relapsed refractory multiple myeloma
Read more →REGNregeneron announces formation of regeneron cell medicines with the acquisition of 2seventy bio platforms and preclinical and clinical programs
regeneron announces formation of regeneron cell medicines with the acquisition of 2seventy bio platforms and preclinical and clinical programs
Read more →REGNdupixent dupilumab fda approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis eoe
dupixent dupilumab fda approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis eoe
Read more →REGNtop 40 high school scientists in prestigious regeneron science talent search to compete for 1 8 million in awards
top 40 high school scientists in prestigious regeneron science talent search to compete for 1 8 million in awards
Read more →REGNdupixent dupilumab u s label updated with data further supporting use in atopic dermatitis with moderate to severe hand and foot involvement
dupixent dupilumab u s label updated with data further supporting use in atopic dermatitis with moderate to severe hand and foot involvement
Read more →REGNJ.P.Morgan Healthcare Conference JANUARY 8, 2024 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially. 2 Strategy & Business Updat
During the J.P. Morgan Healthcare Conference, Regeneron Pharmaceuticals highlighted its significant achievements and upcoming prospects. Notably, EYLEA HD has received FDA approval, aiming to lead in the anti-VEGF treatment market, with strong initial sales indicators. Additionally, Dupixent's global net sales grew 34%, affirming its commercial potential in expanding indications. However, the company acknowledges various risks including regulatory hurdles and competition that could affect future growth.
Read more →REGNregeneron to report fourth quarter and full year 2023 financial and operating results and host conference call and webcast on february 2 2024
regeneron to report fourth quarter and full year 2023 financial and operating results and host conference call and webcast on february 2 2024
Read more →REGNregeneron announces presentation at the 42nd annual j p morgan healthcare conference
regeneron announces presentation at the 42nd annual j p morgan healthcare conference
Read more →REGNregeneron named on dow jones sustainability world index for fifth consecutive year
regeneron named on dow jones sustainability world index for fifth consecutive year
Read more →REGNlatest odronextamab data in relapsed refractory follicular lymphoma showed compelling responses and overall maintenance of patient reported outcomes
latest odronextamab data in relapsed refractory follicular lymphoma showed compelling responses and overall maintenance of patient reported outcomes
Read more →REGNupdated odronextamab data from relapsed refractory diffuse large b cell lymphoma pivotal trial showed deep and durable responses and the potential of ctdna to predict long term out
updated odronextamab data from relapsed refractory diffuse large b cell lymphoma pivotal trial showed deep and durable responses and the potential of ctdna to predict long term out
Read more →REGNupdated linvoseltamab pivotal data demonstrated strong rates and depth of response in patients with heavily pre treated multiple myeloma
updated linvoseltamab pivotal data demonstrated strong rates and depth of response in patients with heavily pre treated multiple myeloma
Read more →REGNregeneron to share progress of novel combination therapies in oncology at esmo io
regeneron to share progress of novel combination therapies in oncology at esmo io
Read more →REGNregeneron to host investor call and webcast on december 14 2023 to provide updates across its hematology portfolio
regeneron to host investor call and webcast on december 14 2023 to provide updates across its hematology portfolio
Read more →REGNdupixent dupilumab significantly reduced copd exacerbations in second positive phase 3 trial accelerating fda submission and confirming potential to become first approved biologic
dupixent dupilumab significantly reduced copd exacerbations in second positive phase 3 trial accelerating fda submission and confirming potential to become first approved biologic
Read more →REGNregeneron commits 34 million over five years to continue to sponsor the regeneron international science and engineering fair isef
regeneron commits 34 million over five years to continue to sponsor the regeneron international science and engineering fair isef
Read more →REGNregeneron to highlight scientific advancements across diversified pipeline in difficult to treat blood cancers and disorders at ash
regeneron to highlight scientific advancements across diversified pipeline in difficult to treat blood cancers and disorders at ash
Read more →REGNRegeneron Reports Third Quarter 2023 Financial and Operating Results Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022 Third quarter 2023 Dupixent global net sales (record
Regeneron Pharmaceuticals announced its financial results for the third quarter of 2023, reporting a 15% increase in revenues to $3.36 billion compared to the previous year. Global net sales for Dupixent reached a record $3.10 billion, marking a 33% rise. Significant pipeline advancements include FDA priority reviews for odronextamab and Dupixent in pediatric eosinophilic esophagitis. However, the company faced a 23% decline in GAAP net income and received a Complete Response Letter for Dupixent regarding chronic spontaneous urticaria, indicating the need for further data.
Read more →REGNregeneron reports third quarter 2023 financial and operating results
regeneron reports third quarter 2023 financial and operating results
Read more →REGNeylea hd aflibercept injection 8 mg data presentations at aao reinforce efficacy and safety profile in wet age related macular degeneration and diabetic macular edema
eylea hd aflibercept injection 8 mg data presentations at aao reinforce efficacy and safety profile in wet age related macular degeneration and diabetic macular edema
Read more →REGNregeneron shares preliminary results showing gene therapy improves auditory responses in child with profound genetic hearing loss
regeneron shares preliminary results showing gene therapy improves auditory responses in child with profound genetic hearing loss
Read more →REGNdupixent dupilumab phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis eoe
dupixent dupilumab phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis eoe
Read more →REGNlibtayo cemiplimab neoadjuvant treatment demonstrates encouraging event free survival in patients with resectable cutaneous squamous cell carcinoma cscc
libtayo cemiplimab neoadjuvant treatment demonstrates encouraging event free survival in patients with resectable cutaneous squamous cell carcinoma cscc
Read more →REGNregeneron and sanofi provide update on dupixent dupilumab sbla for chronic spontaneous urticaria
regeneron and sanofi provide update on dupixent dupilumab sbla for chronic spontaneous urticaria
Read more →REGNregeneron builds on together for change initiative with five year 5 million commitment to fuel the stem talent pipeline in nashville tn
regeneron builds on together for change initiative with five year 5 million commitment to fuel the stem talent pipeline in nashville tn
Read more →REGNtogether for change genomics and equity initiative launched by a coalition of meharry medical college regeneron genetics center astrazeneca novo nordisk and roche to improve health
together for change genomics and equity initiative launched by a coalition of meharry medical college regeneron genetics center astrazeneca novo nordisk and roche to improve health
Read more →REGNregeneron to showcase progress from innovative oncology portfolio in several difficult to treat cancers at esmo
regeneron to showcase progress from innovative oncology portfolio in several difficult to treat cancers at esmo
Read more →REGNeylea hd aflibercept injection 8 mg two year results from pivotal pulsar trial in wet age related macular degeneration presented at euretina
eylea hd aflibercept injection 8 mg two year results from pivotal pulsar trial in wet age related macular degeneration presented at euretina
Read more →REGNregeneron and intellia announce expanded research collaboration to develop crispr based therapies for the treatment of neurological and muscular diseases
regeneron and intellia announce expanded research collaboration to develop crispr based therapies for the treatment of neurological and muscular diseases
Read more →REGNodronextamab bla for treatment of relapsed refractory follicular lymphoma fl and diffuse large b cell lymphoma dlbcl accepted for fda priority review
odronextamab bla for treatment of relapsed refractory follicular lymphoma fl and diffuse large b cell lymphoma dlbcl accepted for fda priority review
Read more →REGNregeneron to report third quarter 2023 financial and operating results and host conference call and webcast on november 2 2023
regeneron to report third quarter 2023 financial and operating results and host conference call and webcast on november 2 2023
Read more →REGNdupixent dupilumab sbla for treatment of eosinophilic esophagitis eoe in children aged 1 to 11 accepted for fda priority review
dupixent dupilumab sbla for treatment of eosinophilic esophagitis eoe in children aged 1 to 11 accepted for fda priority review
Read more →REGNregeneron completes acquisition of decibel therapeutics adding promising gene therapy programs for hearing loss
regeneron completes acquisition of decibel therapeutics adding promising gene therapy programs for hearing loss
Read more →REGNregeneron provides update on planned chief financial officer transition
regeneron provides update on planned chief financial officer transition
Read more →REGNregeneron announces updates to board of directors
regeneron announces updates to board of directors
Read more →REGNregeneron announces agreement with barda supporting development of next generation antibody therapy for covid 19 prevention
regeneron announces agreement with barda supporting development of next generation antibody therapy for covid 19 prevention
Read more →REGNeylea hd aflibercept injection 8 mg approved by fda for treatment of wet age related macular degeneration wamd diabetic macular edema dme and diabetic retinopathy dr
eylea hd aflibercept injection 8 mg approved by fda for treatment of wet age related macular degeneration wamd diabetic macular edema dme and diabetic retinopathy dr
Read more →REGNveopoz pozelimab bbfg receives fda approval as the first treatment for children and adults with chaple disease
veopoz pozelimab bbfg receives fda approval as the first treatment for children and adults with chaple disease
Read more →REGNodronextamab receives ema filing acceptance for treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
odronextamab receives ema filing acceptance for treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
Read more →REGNtwo year pulsar trial results for aflibercept 8 mg demonstrate durable vision gains at extended dosing intervals in wet age related macular degeneration
two year pulsar trial results for aflibercept 8 mg demonstrate durable vision gains at extended dosing intervals in wet age related macular degeneration
Read more →REGNregeneron to acquire decibel therapeutics strengthening gene therapy and hearing loss programs
regeneron to acquire decibel therapeutics strengthening gene therapy and hearing loss programs
Read more →REGNRegeneron Reports Second Quarter 2023 Financial and Operating Results Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022 Second quarter 2023 Dupixent global net sales (re
Regeneron Pharmaceuticals reported strong financial results for the second quarter of 2023, highlighting an 11% revenue increase to $3.16 billion. Key product Dupixent saw global net sales grow by 33% to $2.79 billion. The company is also advancing aflibercept 8 mg towards an anticipated BLA decision in the third quarter, despite receiving a Complete Response Letter from the FDA regarding manufacturing concerns. Additionally, the report mentioned that some trial enrollments are pausing due to adverse events linked to a combination therapy.
Read more →REGNregeneron reports second quarter 2023 financial and operating results
regeneron reports second quarter 2023 financial and operating results
Read more →REGNregeneron announces the 2023 winners of the regeneron prize for creative innovation
regeneron announces the 2023 winners of the regeneron prize for creative innovation
Read more →REGNaflibercept 8 mg two year results from pivotal photon trial in diabetic macular edema presented at asrs
aflibercept 8 mg two year results from pivotal photon trial in diabetic macular edema presented at asrs
Read more →REGNregeneron to report second quarter 2023 financial and operating results and host conference call and webcast on august 3 2023
regeneron to report second quarter 2023 financial and operating results and host conference call and webcast on august 3 2023
Read more →REGNfda issues complete response letter crl for aflibercept 8 mg biologics license application solely due to an ongoing review of inspection findings at a third party filler
fda issues complete response letter crl for aflibercept 8 mg biologics license application solely due to an ongoing review of inspection findings at a third party filler
Read more →REGNtwo year results for aflibercept 8 mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema
two year results for aflibercept 8 mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema
Read more →REGNfianlimab lag 3 inhibitor combined with libtayo cemiplimab shows clinically meaningful and durable tumor responses across key advanced melanoma patient populations
fianlimab lag 3 inhibitor combined with libtayo cemiplimab shows clinically meaningful and durable tumor responses across key advanced melanoma patient populations
Read more →REGNupdated linvoseltamab bcmaxcd3 data from pivotal trial demonstrates early deep and durable responses in patients with heavily pre treated multiple myeloma
updated linvoseltamab bcmaxcd3 data from pivotal trial demonstrates early deep and durable responses in patients with heavily pre treated multiple myeloma
Read more →REGNdupixent dupilumab late breaking phase 3 copd results presented at ats and simultaneously published in the new england journal of medicine
dupixent dupilumab late breaking phase 3 copd results presented at ats and simultaneously published in the new england journal of medicine
Read more →REGNhigh school scientists and engineers win nearly 9 million at the regeneron international science and engineering fair 2023
high school scientists and engineers win nearly 9 million at the regeneron international science and engineering fair 2023
Read more →REGNregeneron applauds supreme court s unanimous opinion striking down amgen s pcsk9 patent claims and supporting scientific innovation
regeneron applauds supreme court s unanimous opinion striking down amgen s pcsk9 patent claims and supporting scientific innovation
Read more →REGNregeneron reports first quarter 2023 financial and operating results
regeneron reports first quarter 2023 financial and operating results
Read more →REGNRegeneron Reports First Quarter 2023 Financial and Operating Results First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022 First quarter 2023 Dupixent global net sales (recorde
Regeneron Pharmaceuticals, Inc. announced its financial results for the first quarter of 2023, highlighting a 7% increase in revenues. Key drivers included a 37% rise in Dupixent global net sales and multiple product approvals. The increase in revenue occurred despite declines in GAAP net income and earnings per share. Positive clinical trial results for Dupixent in COPD and interim data for Alzheimer's therapies showcase Regeneron's promising pipeline of products.
Read more →REGNregeneron to highlight new and updated clinical data at asco showcasing breadth of cancer research
regeneron to highlight new and updated clinical data at asco showcasing breadth of cancer research
Read more →REGNregeneron and alnylam report positive interim phase 1 clinical data on aln app an investigational rnai therapeutic for alzheimer s disease and cerebral amyloid angiopathy
regeneron and alnylam report positive interim phase 1 clinical data on aln app an investigational rnai therapeutic for alzheimer s disease and cerebral amyloid angiopathy
Read more →REGNregeneron announces retirement of board chair dr p roy vagelos accomplished physician businessman and industry luminary
regeneron announces retirement of board chair dr p roy vagelos accomplished physician businessman and industry luminary
Read more →REGNaflibercept 8 mg and eylea aflibercept injection presentations at arvo provide new insights into the treatment of serious retinal diseases
aflibercept 8 mg and eylea aflibercept injection presentations at arvo provide new insights into the treatment of serious retinal diseases
Read more →REGNregeneron to report first quarter 2023 financial and operating results and host conference call and webcast on may 4 2023
regeneron to report first quarter 2023 financial and operating results and host conference call and webcast on may 4 2023
Read more →REGNlibtayo cemiplimab in combination with chemotherapy approved by european commission for the first line treatment of advanced pd l1 positive non small cell lung cancer nsclc
libtayo cemiplimab in combination with chemotherapy approved by european commission for the first line treatment of advanced pd l1 positive non small cell lung cancer nsclc
Read more →REGNregeneron and sonoma biotherapeutics announce collaboration to discover develop and commercialize treg cell therapies for autoimmune diseases
regeneron and sonoma biotherapeutics announce collaboration to discover develop and commercialize treg cell therapies for autoimmune diseases
Read more →REGNdupixent dupilumab demonstrates potential to become first biologic to treat copd by showing significant reduction in exacerbations in pivotal trial
dupixent dupilumab demonstrates potential to become first biologic to treat copd by showing significant reduction in exacerbations in pivotal trial
Read more →REGNfda approves first in class evkeeza evinacumab dgnb for young children with ultra rare form of high cholesterol
fda approves first in class evkeeza evinacumab dgnb for young children with ultra rare form of high cholesterol
Read more →REGNdupixent dupilumab approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
dupixent dupilumab approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Read more →REGNdupixent dupilumab late breaking data at aad show significant improvements in signs and symptoms of moderate to severe atopic hand and foot dermatitis
dupixent dupilumab late breaking data at aad show significant improvements in signs and symptoms of moderate to severe atopic hand and foot dermatitis
Read more →REGNstudents win more than 1 8 million at 2023 regeneron science talent search for remarkable scientific research on rna molecule structure media bias and diagnostics for pediatric hea
students win more than 1 8 million at 2023 regeneron science talent search for remarkable scientific research on rna molecule structure media bias and diagnostics for pediatric hea
Read more →REGNdupixent dupilumab application for treatment of chronic spontaneous urticaria csu in adults and adolescents aged 12 years and older accepted for fda review
dupixent dupilumab application for treatment of chronic spontaneous urticaria csu in adults and adolescents aged 12 years and older accepted for fda review
Read more →REGNkevzara sarilumab approved by fda as first and only biologic indicated for patients with polymyalgia rheumatica
kevzara sarilumab approved by fda as first and only biologic indicated for patients with polymyalgia rheumatica
Read more →REGNlibtayo cemiplimab in combination with chemotherapy receives positive chmp opinion for the treatment of advanced pd l1 positive non small cell lung cancer nsclc
libtayo cemiplimab in combination with chemotherapy receives positive chmp opinion for the treatment of advanced pd l1 positive non small cell lung cancer nsclc
Read more →REGNaflibercept 8 mg bla for treatment of wet age related macular degeneration and diabetic macular edema accepted for fda priority review
aflibercept 8 mg bla for treatment of wet age related macular degeneration and diabetic macular edema accepted for fda priority review
Read more →REGNpozelimab c5 antibody bla for treatment of children and adults with ultra rare chaple disease accepted for fda priority review
pozelimab c5 antibody bla for treatment of children and adults with ultra rare chaple disease accepted for fda priority review
Read more →REGNeylea aflibercept injection approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity rop by the fda
eylea aflibercept injection approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity rop by the fda
Read more →REGNregeneron reports fourth quarter and full year 2022 financial and operating results
regeneron reports fourth quarter and full year 2022 financial and operating results
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021 excluding REGEN-COV and Ronapreve T
Regeneron Pharmaceuticals reported its fourth quarter and full year 2022 financial results, showing a significant decline in overall revenues. Specifically, Q4 revenues decreased by 31%, with total annual revenues dropping 24%. Despite these decreases, the company experienced growth in specific product sales like Dupixent and EYLEA. Regeneron highlighted its advancements in pipeline products, including key approvals and submissions for new therapies.
Read more →REGNdupixent dupilumab approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis
dupixent dupilumab approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Read more →REGNdupixent dupilumab recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis
dupixent dupilumab recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis
Read more →REGNtop 40 high school scientists selected as finalists in the regeneron science talent search the nation s oldest and most prestigious science and math competition
top 40 high school scientists selected as finalists in the regeneron science talent search the nation s oldest and most prestigious science and math competition
Read more →REGNJ.P. Morgan Healthcare Conference
At the J.P. Morgan Healthcare Conference, Regeneron announced significant progress in its strategic initiatives for 2022. Key highlights include positive data for its investigational aflibercept 8 mg and impressive financial results with Dupixent exceeding $6.2 billion in sales. However, the company also acknowledged recent sales challenges due to a shift towards off-label use of Avastin and the temporary closure of a patient assistance fund. Looking forward, Regeneron anticipates potential regulatory approvals and continued growth in multiple therapeutic areas.
Read more →REGNregeneron to report fourth quarter and full year 2022 financial and operating results and host conference call and webcast on february 3 2023
regeneron to report fourth quarter and full year 2022 financial and operating results and host conference call and webcast on february 3 2023
Read more →REGNLibtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
Read more →REGNPositive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Read more →REGNRegeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Read more →REGNDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
Read more →REGNDupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Read more →REGNRegeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
Read more →REGNOdronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
Read more →REGNLinvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
Read more →REGNPivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Read more →REGNRegeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types
Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types
Read more →REGNEvkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review
Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review
Read more →REGNLibtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Read more →REGNRegeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Read more →REGNDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
Read more →REGNLibtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Read more →REGNAflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration
Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration
Read more →REGNRegeneron Reports Third Quarter 2022 Financial and Operating Results
Regeneron Reports Third Quarter 2022 Financial and Operating Results
Read more →REGNRegeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
Read more →REGNRegeneron Reports Third Quarter 2022 Financial and Operating Results Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021 excluding REGEN-COV (a)(b) , revenues increased 11%
Regeneron Reports Third Quarter 2022 Financial and Operating Results Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021 excluding REGEN-COV (a)(b), revenues increased 11% Third quarter 2022 EYLEA U.S. net sales increased 11% versus third quarte
Read more →REGNInmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award
Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award
Read more →REGNRegeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection
Read more →REGNLibtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
Read more →REGNEYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
Read more →REGNDupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
Read more →REGNRegeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022
Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022
Read more →REGNRegeneron Elects Dr. Craig B. Thompson to Board of Directors
Regeneron Elects Dr. Craig B. Thompson to Board of Directors
Read more →REGNAflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Read more →REGNDupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Read more →REGNIntellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Read more →REGNRegeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Read more →REGNPositive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Read more →REGNPositive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Read more →REGNFianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
Read more →REGNNovel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
Read more →REGNRegeneron Announces Investor Call and Webcast at ESMO 2022
Regeneron Announces Investor Call and Webcast at ESMO 2022
Read more →REGNDupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Read more →REGNAflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Read more →REGNLate-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Read more →REGNESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
Read more →REGNRegeneron Reports Second Quarter 2022 Financial and Operating Results Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021 excluding REGEN-COV (a)(b) , revenues increased 2
Regeneron Reports Second Quarter 2022 Financial and Operating Results Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021 excluding REGEN-COV (a)(b), revenues increased 20% Second quarter 2022 EYLEA U.S. net sales increased 14% versus second q
Read more →REGNRegeneron Reports Second Quarter 2022 Financial and Operating Results
Regeneron Reports Second Quarter 2022 Financial and Operating Results
Read more →REGNNovel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Read more →REGNRegeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Read more →REGNRegeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNDupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Read more →REGNRegeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022
Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022
Read more →REGNRegeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
Read more →REGNEYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Read more →REGNIntellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Read more →REGNRegeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
Read more →REGNRegeneron Completes Acquisition of Checkmate Pharmaceuticals
Regeneron Completes Acquisition of Checkmate Pharmaceuticals
Read more →REGNFDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
Read more →REGNEvkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Read more →REGNFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Read more →REGNRegeneron Reports First Quarter 2022 Financial and Operating Results First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021 excluding REGEN-COV (a)(b) , revenues increased 25%
Regeneron Reports First Quarter 2022 Financial and Operating Results First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021 excluding REGEN-COV (a)(b), revenues increased 25% First quarter 2022 EYLEA U.S. net sales increased 13% to $1.52 billion ve
Read more →REGNRegeneron Reports First Quarter 2022 Financial and Operating Results
Regeneron Reports First Quarter 2022 Financial and Operating Results
Read more →REGNRegeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Read more →REGNU.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19
U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19
Read more →REGNDupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Read more →REGNRegeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022
Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022
Read more →REGNFDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Read more →REGNLate-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Read more →REGNIntellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Read more →REGNLate-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis
Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis
Read more →REGNLate-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria
Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria
Read more →REGNRegeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Read more →REGNRegeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
Read more →REGNFDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributab
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV (2) revenues excluding REGEN-COV(1) increased 17% Full y
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Read more →REGNPositive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting
Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting
Read more →REGNCHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Read more →REGNRegeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer
Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer
Read more →REGNForty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search
Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search
Read more →REGNFDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
Read more →REGNSecond Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis
Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
Read more →REGNJP Morgan Healthcare Conference 2022 January 2022 This non - promotional presentation is intended for the investor audience and contains investigational data as well as forward - loo king statements; actual results may v
JP Morgan Healthcare Conference 2022 January 2022 This non - promotional presentation is intended for the investor audience and contains investigational data as well as forward - loo king statements; actual results may vary materially JP Morgan 2022 Current Business Drivers 3 Le
Read more →REGNRegeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States
Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States
Read more →REGNRegeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
Read more →REGNPositive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Read more →REGNNew REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Read more →REGNNew England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma
New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma
Read more →REGNRegeneron to Participate in H.C. Wainwright & Co. Virtual Event
Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
Read more →REGNRegeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
Read more →REGNRegeneron Announces $3 Billion Share Repurchase Program
Regeneron Announces $3 Billion Share Repurchase Program
Read more →REGNRegeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Read more →REGNCHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
Read more →REGNNew Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Read more →REGNRegeneron Reports Third Quarter 2021 Financial and Operating Results
Regeneron Reports Third Quarter 2021 Financial and Operating Results
Read more →REGNRegeneron Reports Third Quarter 2021 Financial and Operating Results Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV (2)
Regeneron Reports Third Quarter 2021 Financial and Operating Results Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV (2) Third quarter 2021 EYLEA U.S. net sales increased 12% versus third quar
Read more →REGNRegeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders
Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders
Read more →REGNSecond Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Read more →REGNDupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease
Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease
Read more →REGNFDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Read more →REGNRegeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021
Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021
Read more →REGNNew REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
Read more →REGNNew England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Read more →REGNFDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
Read more →REGNNew Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
Read more →REGNESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC
ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC
Read more →REGNRegeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail
Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail
Read more →REGNDupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months
Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months
Read more →REGNRegeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
Read more →REGNUK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
Read more →REGNRegeneron Reports Second Quarter 2021 Financial and Operating Results Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-CO
Regeneron Reports Second Quarter 2021 Financial and Operating Results Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COVTM(2) revenues excluding REGEN-COV(1)(2) increased 22% Second quarter 2
Read more →REGNPhase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Read more →REGNNew England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
Read more →REGNRegeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNFDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
Read more →REGNDupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients
Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients
Read more →REGNRegeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
Read more →REGNJapan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
Read more →REGNRegeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021
Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021
Read more →REGNRegeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
Read more →REGNDupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis
Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis
Read more →REGNIntellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Read more →REGNLibtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Read more →REGNRegeneron to Participate in Guggenheim Biopharma Strategy Series
Regeneron to Participate in Guggenheim Biopharma Strategy Series
Read more →REGNREGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Read more →REGNFDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19
FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19
Read more →REGNLibtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
Read more →REGNLibtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers
Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers
Read more →REGNPhase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Read more →REGNPivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children
Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children
Read more →REGNPositive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary
Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary
Read more →REGNRegeneron Reports First Quarter 2021 Financial and Operating Results
Regeneron Reports First Quarter 2021 Financial and Operating Results
Read more →REGNRegeneron Reports First Quarter 2021 Financial and Operating Results First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020 revenues excluding REGEN-COV TM(1) increased 20% Fir
Regeneron Reports First Quarter 2021 Financial and Operating Results First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020 revenues excluding REGEN-COVTM(1) increased 20% First quarter 2021 EYLEA U.S. net sales increased 15% to $1.35 billion versu
Read more →REGNATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupilumab)
ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupilumab)
Read more →REGNNew Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years
New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years
Read more →REGNPhase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
Read more →REGNPhase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)
Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)
Read more →REGNNIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
Read more →REGNNIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
Read more →REGNPhase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Read more →REGNPhase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival
Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival
Read more →REGNFDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
Read more →REGNRegeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Read more →REGNEMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
Read more →REGNIndependent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Read more →REGNFDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Read more →REGNThe Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Read more →REGNU.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation
Read more →REGNFDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
Read more →REGNFDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019 (4) Fourth quarter 2020 EYLEA U.S.
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth quarter 2020 EYLEA U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and f
Read more →REGNNew Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
Read more →REGNREGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa
REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa
Read more →REGNRegeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
Read more →REGNRegeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
Read more →REGNLEONARD S. SCHLEIFER MD, P h D PRESIDENT & CEO GEORGE D. YANCOPOULOS MD, P h D PRESIDENT & CSO JP MORGAN 2021 JANUARY 11 TH 74;This presentation includes forward-looking statements that involve risks and uncertainties re
LEONARD S. SCHLEIFER MD, P h D PRESIDENT & CEO GEORGE D. YANCOPOULOS MD, P h D PRESIDENT & CSO JP MORGAN 2021 JANUARY 11 TH 74; Leonard S. Schleifer MD, PhD President & Chief Executive Officer 3 4 $',9(56,),('*52:7+6725< Dupixent in pivotal trials for eight Type 2 diseases Adva
Read more →REGNRegeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
Read more →REGNNew England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
Read more →REGNRegeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Read more →REGNRegeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
Read more →REGNRegeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
Read more →REGNDupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Read more →REGNRegeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
Read more →REGNRegeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year
Regeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year
Read more →REGNRegeneron Reports Third Quarter 2020 Financial and Operating Results
Regeneron Reports Third Quarter 2020 Financial and Operating Results
Read more →REGNRegeneron Reports Third Quarter 2020 Financial and Operating Results Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019 (4) Third quarter 2020 EYLEA U.S. net sales increase
Regeneron Reports Third Quarter 2020 Financial and Operating Results Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) Third quarter 2020 EYLEA U.S. net sales increased 11% to $1.32 billion versus third quarter 2019 Third quarter 2020 Dupi
Read more →REGNREGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
Read more →REGNFDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Read more →REGNRegeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
Regeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
Read more →REGNRegeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
Read more →REGNDupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
Read more →REGNCHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Read more →REGNRegeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)
Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)
Read more →REGNDupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial
Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial
Read more →REGNRegeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020
Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020
Read more →REGNRegeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Read more →REGNLate-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Read more →REGNPositive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
Read more →REGNRECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
Read more →REGNFDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
Read more →REGNDupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma
Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma
Read more →REGNLate-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO
Late-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO
Read more →REGNRegeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19
Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19
Read more →REGNNew England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Read more →REGNFDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Read more →REGNRegeneron Announces Pricing of Public Offering of Senior Unsecured Notes
Regeneron Announces Pricing of Public Offering of Senior Unsecured Notes
Read more →REGNRegeneron Reports Second Quarter 2020 Financial and Operating Results Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019 (4) Second quarter 2020 EYLEA U.S. net sales were
Regeneron Reports Second Quarter 2020 Financial and Operating Results Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4) Second quarter 2020 EYLEA U.S. net sales were $1.11 billion Second quarter 2020 Dupixent global net sales(2), which a
Read more →REGNTeen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas Burners
Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas Burners
Read more →REGNBARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness
BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness
Read more →REGNRegeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020
Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020
Read more →REGNRegeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
Read more →REGNRegeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
Read more →REGNRegeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients
Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients
Read more →REGNRegeneron to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014
Regeneron to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014
Read more →REGNNew Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab)
New Publication Highlights Preclinical Research Showing Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo® (cemiplimab)
Read more →REGNRegeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNFDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration
Read more →REGNDupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Read more →REGNTwo Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants
Two Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants
Read more →REGNRegeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event
Regeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event
Read more →REGNRegeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
Read more →REGNRegeneron Recognized as Healthcare Sector Leader on "The Civic 50" List of the Most Community-Minded Companies in the United States
Regeneron Recognized as Healthcare Sector Leader on "The Civic 50" List of the Most Community-Minded Companies in the United States
Read more →REGNRegeneron Announces Virtual-Only Format for 2020 Annual Meeting of Shareholders
Regeneron Announces Virtual-Only Format for 2020 Annual Meeting of Shareholders
Read more →REGNRegeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Read more →REGNRegeneron Completes Secondary Offering of Common Stock Held by Sanofi
Regeneron Completes Secondary Offering of Common Stock Held by Sanofi
Read more →REGNLibtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
Read more →REGNRegeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi
Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi
Read more →REGNFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
Read more →REGNDupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
Read more →REGNRegeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio
Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio
Read more →REGNRegeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
Read more →REGNLibtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Read more →REGNRegeneron Reports First Quarter 2020 Financial and Operating Results First quarter 2020 revenues increased 33% to $1.83 billion versus first quarter 2019 (4) First quarter EYLEA U.S. net sales increased 9%
Regeneron Reports First Quarter 2020 Financial and Operating Results Tarrytown, New York (May 5, 2020) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2020 and provided a business update. "Over 30 years, the Regeneron
Read more →REGNRegeneron Announces Upcoming Investor Conference Presentations
Regeneron Announces Upcoming Investor Conference Presentations
Read more →REGNRegeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
Read more →REGNPhase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
Read more →REGNFDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
Read more →REGNRegeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Read more →REGNRegeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation
Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation
Read more →REGNDupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Read more →REGNRegeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
Read more →REGNFirst patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
Read more →REGNRegeneron Announces Important Advances in Novel COVID-19 Antibody Program
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
Read more →REGNEYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy
EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results Fourth quarter 2019 revenues increased 13% to $2.17 billion versus fourth quarter 2018 Fourth quarter EYLEA U.S. net sales
Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results Tarrytown, New York (February 6, 2020) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2019 and provided a business update
Read more →REGNRegeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
Read more →REGNFDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Read more →REGNForty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020
Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020
Read more →REGNLEONARD S. SCHLEIFER MD, P h D PRESIDENT & CEO GEORGE D. YANCOPOULOS MD, P h D PRESIDENT & CSO JP MORGAN 2020 JANUARY 13 TH 2 NOTE REGARDING FORWARD - LOOKING STATEMENTS AND NON - GAAP FINANCIAL MEASURES This presentatio
LEONARD S. SCHLEIFER MD, P h D PRESIDENT & CEO GEORGE D. YANCOPOULOS MD, P h D PRESIDENT & CSO JP MORGAN 2020 JANUARY 13 TH 3 A DECADE OF INNOVATION, VALUE CREATION, AND TRANSFORMATION 2010 2020 * Includes products marketed by Regeneron and/or its collaborators, based on trailin
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020
Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020
Read more →REGNRegeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
Read more →REGNPublication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy
Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy
Read more →REGNRegeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Read more →REGNSociety for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair
Society for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair
Read more →REGNRegeneron and Cold Spring Harbor Laboratory Unveil New Dedicated Laboratories for Student Science Education
Regeneron and Cold Spring Harbor Laboratory Unveil New Dedicated Laboratories for Student Science Education
Read more →REGNRegeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Read more →REGNFirst Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
Read more →REGNRegeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
Read more →REGNNew England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Read more →REGNRegeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award
Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award
Read more →REGNRegeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Read more →REGNRegeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting
Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting
Read more →REGNRegeneron Reports Third Quarter 2019 Financial and Operating Results
Regeneron Reports Third Quarter 2019 Financial and Operating Results
Read more →REGNRegeneron Reports Third Quarter 2019 Financial and Operating Results Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA U.S. net sales increased 16% to
Regeneron Reports Third Quarter 2019 Financial and Operating Results Tarrytown, New York (November 5, 2019) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2019 and provided a business update. "Regeneron delivered pos
Read more →REGNRegeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Read more →REGNDupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis
Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis
Read more →REGNRegeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For
Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For
Read more →REGNRegeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good
Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good
Read more →REGNRegeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019
Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019
Read more →REGNThe Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Read more →REGNCHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
Read more →REGNEducational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis
Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis
Read more →REGNRegeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies
Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies
Read more →REGNU.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
Read more →REGNRegeneron Announces Upcoming Investor Conference Presentation
Regeneron Announces Upcoming Investor Conference Presentation
Read more →REGNRegeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Read more →REGNFDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe
FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe
Read more →REGNPALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
Read more →REGNDupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Read more →REGNDupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron Reports Second Quarter 2019 Financial and Operating Results Second quarter 2019 revenues increased 20% to $1.93 billion versus second quarter 2018 EYLEA U.S. net sales increased 17% to $1.16 billi
Regeneron Reports Second Quarter 2019 Financial and Operating Results Tarrytown, New York (August 6, 2019) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2019 and provided a business update. "We had a great quarter
Read more →REGNRegeneron Reports Second Quarter 2019 Financial and Operating Results
Regeneron Reports Second Quarter 2019 Financial and Operating Results
Read more →REGNRegeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNRegeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019
Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019
Read more →REGNLibtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
Read more →REGNCHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Read more →REGNFDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
Read more →REGNRegeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
Read more →REGNRegeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
Read more →REGNUpdated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNFDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
Read more →REGNRegeneron Reports First Quarter 2019 Financial and Operating Results First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018 First quarter 2019 EYLEA (aflibercept) Injection U.S
Regeneron Reports First Quarter 2019 Financial and Operating Results Tarrytown, New York (May 7, 2019) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2019 and provided a business update. "In the first quarter, aggreg
Read more →REGNRegeneron Reports First Quarter 2019 Financial and Operating Results
Regeneron Reports First Quarter 2019 Financial and Operating Results
Read more →REGNDupixent® (dupilumab) Approved for Severe Asthma by European Commission
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Read more →REGNFDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
Read more →REGNCHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNRegeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
Read more →REGNRegeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Read more →REGNPraluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Read more →REGNRegeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19
Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19
Read more →REGNTeen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Read more →REGNNew Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
Read more →REGNFDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Read more →REGNRegeneron Announces Upcoming Investor Conference Call
Regeneron Announces Upcoming Investor Conference Call
Read more →REGNFDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Read more →REGNNew Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis
New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis
Read more →REGNCHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication
CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication
Read more →REGNRegeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Read more →REGNPositive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Read more →REGNU.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor
U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor
Read more →REGNRegeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price
Regeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price
Read more →REGNOne-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results Fourth quarter 2018 revenues were $1.93 billion , an increase of 22% - Fourth quarter 2018 EYLEA (aflibercept) Injection U
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results Tarrytown, New York (February 6, 2019) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2018 and provided a business update
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
Read more →REGNCHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Read more →REGNForty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
Read more →REGNRegeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Read more →REGNRegeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference TARRYTOWN, N.Y. (
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference TARRYTOWN, N.Y. (January 7, 2019) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will provide a strategic business update to the investor community today at the 37 th Annual J.P.
Read more →REGNRegeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Read more →REGNRegeneron Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Read more →REGNRegeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Read more →REGNODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
Read more →REGNNew England Journal of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial
New England Journal of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial
Read more →REGNRegeneron Reports Third Quarter 2018 Financial and Operating Results
Regeneron Reports Third Quarter 2018 Financial and Operating Results
Read more →REGNFDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron Reports Third Quarter 2018 Financial and Operating Results Third quarter 2018 EYLEA (aflibercept) Injection U.S. net sales increased 7% to $1.02 billion versus third quarter 2017, and third quarte
Regeneron Reports Third Quarter 2018 Financial and Operating Results Tarrytown, New York (November 6, 2018) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2018 and provided a business update. "Regeneron continues to
Read more →REGNRegeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine
Regeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine
Read more →REGNEYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Read more →REGNFDA Approves Asthma Indication for Dupixent® (dupilumab)
FDA Approves Asthma Indication for Dupixent® (dupilumab)
Read more →REGNKevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis
Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis
Read more →REGNDupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps
Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps
Read more →REGNSUPREME COURT OF THE STATE OF NEW YORK COUNTY OF NEW YORK: PART 39 ---------------------------------------------------------------------------X : PUBLIC EMPLOYEES RETIREMENT SYSTEM OF MISSISSIPPI, : Index No. 656813/2017
NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTIONS TO: ALL RECORD AND BENEFICIAL HOLDERS OF THE CLASS A OR COMMON STOCK OF REGENERON PHARMACEUTICALS, INC. ( REGENERON OR THE COMPANY ) ( REGENERON SHAREHOLDERS ) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE
Read more →REGNRegeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018
Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018
Read more →REGNLibtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Read more →REGNFDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNPositive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Read more →REGNFDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Read more →REGNFDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Read more →REGNFDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Read more →REGNRegeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Read more →REGNRegeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Read more →REGNRegeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Read more →REGNRegeneron Announces the 2018 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces the 2018 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNRegeneron Reports Second Quarter 2018 Financial and Operating Results
Regeneron Reports Second Quarter 2018 Financial and Operating Results
Read more →REGNRegeneron Reports Second Quarter 2018 Financial and Operating Results Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and second quarter 2018 non-G
Regeneron Reports Second Quarter 2018 Financial and Operating Results Tarrytown, New York (August 2, 2018) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2018 and provided a business update. "Regeneron made importan
Read more →REGNRegeneron to Report Second Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on August 2, 2018
Regeneron to Report Second Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on August 2, 2018
Read more →REGNRegeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health
Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health
Read more →REGNNew England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNRegeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak
Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak
Read more →REGNNew England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma
New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma
Read more →REGNRegeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
Read more →REGNPositive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
Read more →REGNRegeneron Reports First Quarter 2018 Financial and Operating Results
Regeneron Reports First Quarter 2018 Financial and Operating Results
Read more →REGNRegeneron Reports First Quarter 2018 Financial and Operating Results First quarter 2018 GAAP net income per diluted share increased by 93% to $4.16 versus first quarter 2017 and first quarter 2018 non-GAAP
Regeneron Reports First Quarter 2018 Financial and Operating Results Tarrytown, New York (May 3, 2018) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2018 and provided a business update. "Regeneron's commercial busin
Read more →REGNRegeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
Read more →REGNFDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNRegeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018
Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018
Read more →REGNEMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNEMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
Read more →REGNRegeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease
Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease
Read more →REGNEYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Read more →REGNTeen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease
Read more →REGNRegeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
Read more →REGNPraluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate
Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate
Read more →REGNFDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Read more →REGNRegeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results Fourth quarter 2017 GAAP net income per diluted share decreased by 32% to $1.50 versus fourth quarter 2016, and includes a
Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results Tarrytown, New York (February 8, 2018) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2017 and provided a business update
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018
Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018
Read more →REGNRegeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Read more →REGNRegeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
Read more →REGNRegeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank
Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank
Read more →REGNJP Morgan 2018 Leonard S. Schleifer MD, PhD, President & CEO George D. Yancopoulos MD, PhD, President & CSO January 8th, 2018 Safe Harbor Statement circa 1988 2 Regeneron is a risky investment. That we hope will pay off
JP Morgan 2018 Leonard S. Schleifer MD, PhD, President & CEO George D. Yancopoulos MD, PhD, President & CSO January 8th, 2018 Safe Harbor Statement circa 1988 2 Regeneron is a risky investment. That we hope will pay off handsomely! The early days ATING NEURONS Founded by physic
Read more →REGNRegeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference
Read more →REGNRegeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration
Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration
Read more →REGNRegeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNRegeneron Collaboration Programs Highlighted During Sanofi Analyst Day
Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day
Read more →REGNRegeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD
Read more →REGNRegeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Read more →REGNRegeneron Reports Third Quarter 2017 Financial and Operating Results
Regeneron Reports Third Quarter 2017 Financial and Operating Results
Read more →REGNRegeneron Reports Third Quarter 2017 Financial and Operating Results Third quarter 2017 EYLEA (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016 Third quarter 201
Regeneron Reports Third Quarter 2017 Financial and Operating Results Tarrytown, New York (November 8, 2017) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2017 and provided a business update. Financial Highlights
Read more →REGNRegeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
Read more →REGNRegeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting
Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting
Read more →REGNDupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
Read more →REGNRegeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations
Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations
Read more →REGNScience Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time
Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time
Read more →REGNRegeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Read more →REGNRegeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
Read more →REGNInternationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Read more →REGNAppellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Read more →REGNRegeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens
Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens
Read more →REGNRegeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Read more →REGNRegeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Read more →REGNRegeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Read more →REGNRegeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Read more →REGNRegeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
Read more →REGNRegeneron Reports Second Quarter 2017 Financial and Operating Results Second quarter 2017 EYLEA (aflibercept) Injection U.S. net sales increased 11% to $919 million versus second quarter 2016 Second quarter
Regeneron Reports Second Quarter 2017 Financial and Operating Results Tarrytown, New York (August 3, 2017) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2017 and provided a business update. Financial Highlights
Read more →REGNAccessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast
Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast
Read more →REGNRegeneron Reports Second Quarter 2017 Financial and Operating Results
Regeneron Reports Second Quarter 2017 Financial and Operating Results
Read more →REGNRegeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNRegeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017
Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017
Read more →REGNRegeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Read more →REGNRegeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885)
Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885)
Read more →REGNRegeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States
Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States
Read more →REGNRegeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Read more →REGNRegeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Read more →REGNRegeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH
Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH
Read more →REGNRegeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
Read more →REGNRegeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Read more →REGNRegeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer
Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer
Read more →REGNRegeneron Reports First Quarter 2017 Financial and Operating Results
Regeneron Reports First Quarter 2017 Financial and Operating Results
Read more →REGNRegeneron Reports First Quarter 2017 Financial and Operating Results First quarter 2017 EYLEA (aflibercept) Injection U.S. net sales increased 9% to $854 million versus first quarter 2016 First quarter 2017
Regeneron Reports First Quarter 2017 Financial and Operating Results Tarrytown, New York (May 4, 2017) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2017 and provided a business update. Financial Highlights ($ i
Read more →REGNSurvey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
Read more →REGNRegeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Read more →REGNRegeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Read more →REGNRegeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Read more →REGNRegeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017
Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017
Read more →REGNRegeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
Read more →REGNRegeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval
Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval
Read more →REGNU.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis
U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis
Read more →REGNTeen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017
Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017
Read more →REGNRegeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Read more →REGNRegeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
Read more →REGNRegeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Read more →REGNRegeneron Announces Upcoming 2017 Investor Conference Presentations
Regeneron Announces Upcoming 2017 Investor Conference Presentations
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results Fourth quarter 2016 EYLEA (aflibercept) Injection U.S. net sales increased 15% to $858 million versus fourth quarter 2015
Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results Tarrytown, New York (February 9, 2017) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2016 and provided a business update
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results
Read more →REGNAppeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process
Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2017
Regeneron to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2017
Read more →REGNRegeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada
Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada
Read more →REGNTony Coles, M.D., Elected to Regeneron Board of Directors
Tony Coles, M.D., Elected to Regeneron Board of Directors
Read more →REGNForty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists
Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists
Read more →REGNRegeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
Read more →REGNRegeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Read more →REGNScience Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System
Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System
Read more →REGNRegeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Read more →REGNRegeneron Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference
Read more →REGNRegeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
Read more →REGNRegeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year
Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year
Read more →REGNRegeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Read more →REGNRegeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
Read more →REGNRegeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Read more →REGNRegeneron Reports Third Quarter 2016 Financial and Operating Results
Regeneron Reports Third Quarter 2016 Financial and Operating Results
Read more →REGNRegeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis
Regeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis
Read more →REGNScience Magazine Once Again Names Regeneron the Best Company to Work For
Science Magazine Once Again Names Regeneron the Best Company to Work For
Read more →REGNRegeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference
Regeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference
Read more →REGNRegeneron and Teva Provide Update on Fasinumab Clinical Development Programs
Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
Read more →REGNRegeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016
Regeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016
Read more →REGNNew Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease
New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease
Read more →REGNRegeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
Read more →REGNRegeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
Read more →REGNRegeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Read more →REGNRegeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Read more →REGNRegeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Read more →REGNRegeneron Announces Upcoming 2016 Investor Conference Presentations
Regeneron Announces Upcoming 2016 Investor Conference Presentations
Read more →REGNRegeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Read more →REGNRegeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
Read more →REGNRegeneron Announces Upcoming 2016 Investor Conference Presentation
Regeneron Announces Upcoming 2016 Investor Conference Presentation
Read more →REGNRegeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNAward-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease
Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease
Read more →REGNRegeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016
Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016
Read more →REGNRegeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Read more →REGNRegeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Read more →REGNRegeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
Read more →REGNRegeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
Read more →REGNRegeneron Reports First Quarter 2016 Financial and Operating Results
Regeneron Reports First Quarter 2016 Financial and Operating Results
Read more →REGNRegeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Read more →REGNRegeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016
Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016
Read more →REGNRegeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Read more →REGNRegeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Read more →REGNRegeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Read more →REGNRegeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Read more →REGNRegeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Read more →REGNRegeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Read more →REGNRegeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease
Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016
Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016
Read more →REGNRegeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA
Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA
Read more →REGNRegeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference
Read more →REGNRegeneron Mourns Passing of Dr. Alfred G. Gilman, Board Member and Nobel Laureate
Regeneron Mourns Passing of Dr. Alfred G. Gilman, Board Member and Nobel Laureate
Read more →REGNRegeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
Read more →REGNRegeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled
Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled
Read more →REGNRegeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Read more →REGNRegeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Read more →REGNNew Survey Of U.S. Adults With Diabetes Reveals Less Than Half Understand Their Risk For Vision Loss
New Survey Of U.S. Adults With Diabetes Reveals Less Than Half Understand Their Risk For Vision Loss
Read more →REGNRegeneron Reports Third Quarter 2015 Financial and Operating Results
Regeneron Reports Third Quarter 2015 Financial and Operating Results
Read more →REGNRegeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Read more →REGNRegeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference
Regeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference
Read more →REGNRegeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2015
Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2015
Read more →REGNRegeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
Read more →REGNRegeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Read more →REGNRegeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement
Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement
Read more →REGNRegeneron Announces Agreement with BARDA for the Development of New Antibody Treatment for Ebola
Regeneron Announces Agreement with BARDA for the Development of New Antibody Treatment for Ebola
Read more →REGNRegeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
Read more →REGNRegeneron Announces Upcoming 2015 Investor Conference Presentations
Regeneron Announces Upcoming 2015 Investor Conference Presentations
Read more →REGNRegeneron and Sanofi Launch Major New Immuno-Oncology Collaboration
Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration
Read more →REGNRegeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Read more →REGNRegeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia
Read more →REGNRegeneron to Report Second Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2015
Regeneron to Report Second Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2015
Read more →REGNRegeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection
Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection
Read more →REGNNew Film Documents Heart Felt Stories of People Living with High LDL Cholesterol
New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol
Read more →REGNRegeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication
Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication
Read more →REGNEYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
Read more →REGNRegeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation
Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation
Read more →REGNTrading in Regeneron Common Stock Halted
Trading in Regeneron Common Stock Halted
Read more →REGNFDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
Read more →REGNRegeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Read more →REGNRegeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference
Read more →REGNRegeneron Reports First Quarter 2015 Financial and Operating Results
Regeneron Reports First Quarter 2015 Financial and Operating Results
Read more →REGNRegeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015
Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015
Read more →REGNEYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)
EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)
Read more →REGNRegeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine
Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine
Read more →REGNEYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Read more →REGNNIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab
NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab
Read more →REGNNew Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels
New Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
Read more →REGNRegeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Read more →REGNEYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
Read more →REGNRegeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA
Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA
Read more →REGNRegeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia
Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015
Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015
Read more →REGNRegeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference
Read more →REGNHave You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol
Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol
Read more →REGNEYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema
EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Read more →REGNRegeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Read more →REGNRegeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
Read more →REGNRegeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
Read more →REGNRegeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
Read more →REGNRegeneron Reports Third Quarter 2014 Financial and Operating Results
Regeneron Reports Third Quarter 2014 Financial and Operating Results
Read more →REGNRegeneron Announces Upcoming 2014 Investor Conference Presentations
Regeneron Announces Upcoming 2014 Investor Conference Presentations
Read more →REGNRegeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Read more →REGNEYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Read more →REGNRegeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments
Read more →REGNRegeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year
Read more →REGNRegeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014
Read more →REGNEYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
Read more →REGNRegeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Read more →REGNRegeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Read more →REGNEYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Read more →REGNRegeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Read more →REGNRegeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Read more →REGNRegeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Read more →REGNEYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Read more →REGNRegeneron Reports Second Quarter 2014 Financial and Operating Results
Regeneron Reports Second Quarter 2014 Financial and Operating Results
Read more →REGNRegeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Read more →REGNRegeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Read more →REGNEYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
Read more →REGNRegeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Read more →REGNTwo-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Read more →REGNRegeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Read more →REGNEYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Read more →REGNSanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Read more →REGNEYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Read more →REGNRegeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation
Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation
Read more →REGNRegeneron Announces Update to Upcoming 2014 Investor Conference Presentations
Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations
Read more →REGNRegeneron Reports First Quarter 2014 Financial and Operating Results
Regeneron Reports First Quarter 2014 Financial and Operating Results
Read more →REGNRegeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014
Regeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014
Read more →REGNRobert A. Ingram Elected to Regeneron Board of Directors
Robert A. Ingram Elected to Regeneron Board of Directors
Read more →REGNRegeneron Announces Initiative for STEM Education in Hudson Valley
Regeneron Announces Initiative for STEM Education in Hudson Valley
Read more →REGNSanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study
Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study
Read more →REGNSanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
Read more →REGNBayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan
Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan
Read more →REGNRegeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Read more →REGNTwo-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014
Read more →REGNRegeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration
Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration
Read more →REGNRegeneron Announces Amendment to Investor Agreement with Sanofi
Regeneron Announces Amendment to Investor Agreement with Sanofi
Read more →REGNRegeneron Launches New Human Genetics Initiative
Regeneron Launches New Human Genetics Initiative
Read more →REGNSanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program
Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program
Read more →REGNRegeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Read more →REGNRegeneron Announces Presentation at the 32nd Annual J. P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 32nd Annual J. P. Morgan Healthcare Conference
Read more →REGNRegeneron Announces Upcoming 2013 Investor Conference Presentation
Regeneron Announces Upcoming 2013 Investor Conference Presentation
Read more →REGNRegeneron's Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
Regeneron's Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
Read more →REGNSanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Read more →REGNEYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Read more →REGNRegeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting
Regeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting
Read more →REGNEYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema
EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema
Read more →REGNRegeneron Reports Third Quarter 2013 Financial and Operating Results
Regeneron Reports Third Quarter 2013 Financial and Operating Results
Read more →REGNRegeneron Announces Upcoming 2013 Investor Conference Presentations
Regeneron Announces Upcoming 2013 Investor Conference Presentations
Read more →REGNRegeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Read more →REGNRegeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion
Regeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion
Read more →REGNSanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Read more →REGNRegeneron to Report Third Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2013
Regeneron to Report Third Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2013
Read more →REGNRegeneron to Present Phase 3 Data for EYLEA® (aflibercept) Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting
Regeneron to Present Phase 3 Data for EYLEA® (aflibercept) Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting
Read more →REGNRegeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Read more →REGNRegeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice
Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice
Read more →REGNRegeneron and Bayer Report Positive One-Year Results from Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema
Regeneron and Bayer Report Positive One-Year Results from Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema
Read more →REGNRegeneron Reports Second Quarter 2013 Financial and Operating Results
Regeneron Reports Second Quarter 2013 Financial and Operating Results
Read more →REGNEYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Read more →REGNRegeneron to Report Second Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2013
Regeneron to Report Second Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2013
Read more →REGNRegeneron Announces First Recipients of Annual "Regeneron Prize for Creative Innovation"
Regeneron Announces First Recipients of Annual "Regeneron Prize for Creative Innovation"
Read more →REGNRegeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)
Regeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)
Read more →REGNSanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Read more →REGNSanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Read more →REGNRegeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
Read more →REGNRegeneron Reports First Quarter 2013 Financial and Operating Results
Regeneron Reports First Quarter 2013 Financial and Operating Results
Read more →REGNRegeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Read more →REGNRegeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley
Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley
Read more →REGNRegeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Read more →REGNRegeneron Announces Receipt of Hart-Scott-Rodino Notice
Regeneron Announces Receipt of Hart-Scott-Rodino Notice
Read more →REGNZALTRAP® (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
ZALTRAP® (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Read more →REGNRegeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
Read more →REGNRegeneron Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
Regeneron Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
Read more →REGNRegeneron Announces January 2013 Investor Conference Presentations
Regeneron Announces January 2013 Investor Conference Presentations
Read more →REGNRegeneron Named Biotechnology Company of the Year
Regeneron Named Biotechnology Company of the Year
Read more →REGNEYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Read more →REGNRegeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
Read more →REGNZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
ZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
Read more →REGNRegeneron Announces November 2012 Investor Conference Presentations
Regeneron Announces November 2012 Investor Conference Presentations
Read more →REGNSanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Read more →REGNSanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Read more →REGNRegeneron Reports Third Quarter 2012 Financial and Operating Results
Regeneron Reports Third Quarter 2012 Financial and Operating Results
Read more →REGNRegeneron Announces Publication of EYLEA® (aflibercept) Injection Phase 3 VIEW 1 and VIEW 2 Studies in Ophthalmology
Regeneron Announces Publication of EYLEA® (aflibercept) Injection Phase 3 VIEW 1 and VIEW 2 Studies in Ophthalmology
Read more →REGNRegeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Read more →REGNEYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Read more →REGNRegeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion
Regeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion
Read more →REGNRegeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Read more →REGNRegeneron Announces September 2012 Investor Conference Presentations
Regeneron Announces September 2012 Investor Conference Presentations
Read more →REGNRegeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies
Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies
Read more →REGNRegeneron Reports Second Quarter 2012 Financial and Operating Results
Regeneron Reports Second Quarter 2012 Financial and Operating Results
Read more →REGNRegeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Read more →REGNRegeneron Announces June 2012 Investor Conference Presentations
Regeneron Announces June 2012 Investor Conference Presentations
Read more →REGNRegeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
Read more →REGNRegeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
Read more →REGNRegeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Read more →REGNRegeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Read more →REGNRegeneron Reports First Quarter 2012 Financial and Operating Results
Regeneron Reports First Quarter 2012 Financial and Operating Results
Read more →REGNRegeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
Read more →REGNSanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept)
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept)
Read more →REGNRegeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Read more →REGNRegeneron Announces Change in Date for Presentation at Barclays Capital 2012 Global Healthcare Conference
Regeneron Announces Change in Date for Presentation at Barclays Capital 2012 Global Healthcare Conference
Read more →REGNRegeneron and Bayer Announce Approval of EYLEA® (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Regeneron and Bayer Announce Approval of EYLEA® (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Read more →REGNRegeneron Announces March 2012 Investor Conference Presentations
Regeneron Announces March 2012 Investor Conference Presentations
Read more →REGNRegeneron Announces February 2012 Investor Conference Presentations
Regeneron Announces February 2012 Investor Conference Presentations
Read more →REGNRegeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Read more →REGNRegeneron Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast
Regeneron Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast
Read more →REGNRegeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Read more →REGNRegeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference
Read more →REGNRegeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Read more →REGNRegeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Read more →REGNTwo Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
Read more →REGNRegeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Read more →REGNRegeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China
Regeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China
Read more →REGNRegeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Read more →REGNRegeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Read more →REGNMultimedia: Regeneron Announces FDA Approval of EYLEA™ (Aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Multimedia: Regeneron Announces FDA Approval of EYLEA™ (Aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Read more →REGNSanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Read more →REGNRegeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference
Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference
Read more →REGNRegeneron Reports Third Quarter 2011 Financial and Operating Results
Regeneron Reports Third Quarter 2011 Financial and Operating Results
Read more →REGNRegeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Read more →REGNRegeneron Announces September 2011 Investor Conference Presentations
Regeneron Announces September 2011 Investor Conference Presentations
Read more →REGNRegeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Read more →REGNRegeneron Reports Second Quarter 2011 Financial and Operating Results
Regeneron Reports Second Quarter 2011 Financial and Operating Results
Read more →REGNPhase 3 Trial of ZALTRAP™ (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Phase 3 Trial of ZALTRAP™ (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Read more →REGNEYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
EYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Read more →REGNRegeneron Announces EYLEA™ (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee
Regeneron Announces EYLEA™ (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee
Read more →REGNVEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
Read more →REGNZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Read more →REGNFDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Read more →REGNRegeneron Reports First Quarter 2011 Financial and Operating Results
Regeneron Reports First Quarter 2011 Financial and Operating Results
Read more →REGNRegeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
Read more →REGNRegeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Read more →REGNSanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP™ (aflibercept) in Second-line Metastatic Colorectal Cancer
Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP™ (aflibercept) in Second-line Metastatic Colorectal Cancer
Read more →REGNFDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Read more →REGNRegeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Read more →REGNRegeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
Read more →REGNSanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Read more →REGNARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Read more →REGNRegeneron Announces March 2011 Investor Conference Presentations
Regeneron Announces March 2011 Investor Conference Presentations
Read more →REGNRegeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Read more →REGNRegeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Read more →REGNRegeneron Announces Presentation at the ISI Annual Conference
Regeneron Announces Presentation at the ISI Annual Conference
Read more →REGNRegeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
Read more →REGNRegeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Read more →REGNRegeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Read more →REGNRegeneron Announces Presentation at the 2010 Deutsche Bank BioFest
Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
Read more →REGNRegeneron Announces Presentation at the 22nd Annual Piper Jaffray Healthcare Conference
Regeneron Announces Presentation at the 22nd Annual Piper Jaffray Healthcare Conference
Read more →REGNBayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
Read more →REGNRegeneron Schedules November 22, 2010 Teleconference and Webcast to Discuss Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
Regeneron Schedules November 22, 2010 Teleconference and Webcast to Discuss Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
Read more →REGNChristine A. Poon Elected to Regeneron Board of Directors
Christine A. Poon Elected to Regeneron Board of Directors
Read more →REGNRegeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
Read more →REGNRegeneron Reports Third Quarter 2010 Financial Results and Business Highlights
Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights
Read more →REGNRegeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
Read more →REGNRegeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Read more →REGNRegeneron Increases Size of Public Offering of Common Stock
Regeneron Increases Size of Public Offering of Common Stock
Read more →REGNRegeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
Read more →REGNRegeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day
Regeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day
Read more →REGNRegeneron Announces Presentation at the UBS Global Life Sciences Conference
Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Read more →REGNPhase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Read more →REGNRegeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
Read more →REGNRegeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Read more →REGNRegeneron Reports Second Quarter 2010 Financial and Operating Results
Regeneron Reports Second Quarter 2010 Financial and Operating Results
Read more →REGNAstellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023
Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023
Read more →REGNRegeneron to Webcast Investor Day on July 15, 2010
Regeneron to Webcast Investor Day on July 15, 2010
Read more →REGNRegeneron Announces Presentation at the Goldman Sachs 31st Annual Global Healthcare Conference
Regeneron Announces Presentation at the Goldman Sachs 31st Annual Global Healthcare Conference
Read more →REGNARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy
Read more →REGNRegeneron Schedules June 9, 2010 Teleconference and Webcast to Discuss Phase 3 Trial Results in Gout
Regeneron Schedules June 9, 2010 Teleconference and Webcast to Discuss Phase 3 Trial Results in Gout
Read more →REGNRegeneron Announces Presentation at the 9th Annual Needham Healthcare Conference
Regeneron Announces Presentation at the 9th Annual Needham Healthcare Conference
Read more →REGNRegeneron Announces Presentation at the 2010 Citi Investment Research Global Healthcare Conference
Regeneron Announces Presentation at the 2010 Citi Investment Research Global Healthcare Conference
Read more →REGNRegeneron Provides Initial Data on Two Antibody Product Candidates
Regeneron Provides Initial Data on Two Antibody Product Candidates
Read more →REGNRegeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Healthcare Conference
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Healthcare Conference
Read more →REGNRegeneron Reports First Quarter 2010 Financial and Operating Results
Regeneron Reports First Quarter 2010 Financial and Operating Results
Read more →REGNRegeneron Announces Appointment of Michael Aberman, M.D., as Vice President, Strategy and Investor Relations
Regeneron Announces Appointment of Michael Aberman, M.D., as Vice President, Strategy and Investor Relations
Read more →REGNRegeneron Announces Presentation at the Barclays Capital Global 2010 Healthcare Conference
Regeneron Announces Presentation at the Barclays Capital Global 2010 Healthcare Conference
Read more →REGNRegeneron Announces Presentation at the Cowen and Company 30th Annual Healthcare Conference
Regeneron Announces Presentation at the Cowen and Company 30th Annual Healthcare Conference
Read more →REGNRegeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference
Regeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference
Read more →REGNVEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema
VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema
Read more →REGNRegeneron Reports Full Year and Fourth Quarter 2009 Financial and Operating Results
Regeneron Reports Full Year and Fourth Quarter 2009 Financial and Operating Results
Read more →REGNRegeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference
Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference
Read more →REGNSanofi-aventis and Regeneron Expand Strategic Antibody Collaboration New agreements expand and extend November 2007 antibody collaboration Collaboration goal is to advance 4 to 5 antibodies per year into clinical development Sanofi-aventis to fund up to $160M annually for Regeneron antibody
Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration New agreements expand and extend November 2007 antibody collaboration Collaboration goal is to advance 4 to 5 antibodies per year into clinical development Sanofi-aventis to fund up to $160M annually for Regeneron antibody
Read more →REGNRegeneron Reports Third Quarter 2009 Financial and Operating Results
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Read more →REGNEnrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-related Macular Degeneration (Wet AMD) One-year primary endpoint data
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-related Macular Degeneration (Wet AMD) One-year primary endpoint data
Read more →REGNPhase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed
Read more →REGNRegeneron Reports Second Quarter 2009 Financial and Operating Results
Regeneron Reports Second Quarter 2009 Financial and Operating Results
Read more →REGNSanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
Read more →REGNRegeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement
Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement
Read more →REGNRegeneron Reports First Quarter 2009 Financial and Operating Results
Regeneron Reports First Quarter 2009 Financial and Operating Results
Read more →REGNRegeneron Reports Full Year and Fourth Quarter 2008 Financial and Operating Results
Regeneron Reports Full Year and Fourth Quarter 2008 Financial and Operating Results
Read more →REGN27th Annual J. P. Morgan Healthcare Conference January 2009 Except for historical information, the matters contained in this presentation may constitute forward-looking statements that involve risks and uncertainties, including uncertainties related to product development and
27th Annual J. P. Morgan Healthcare Conference January 2009 Except for historical information, the matters contained in this presentation may constitute forward-looking statements that involve risks and uncertainties, including uncertainties related to product development and
Read more →REGNRegeneron Reports Third Quarter 2008 Financial and Operating Results
Regeneron Reports Third Quarter 2008 Financial and Operating Results
Read more →REGNTop-line Results of a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Rilonacept (IL-1 Trap) for the Prevention of Gout Flares During Initiation of Allopurinol Therapy
Top-line Results of a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Rilonacept (IL-1 Trap) for the Prevention of Gout Flares During Initiation of Allopurinol Therapy
Read more →REGNRegeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent
Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent
Read more →REGNRegeneron Reports Second Quarter 2008 Financial and Operating Results
Regeneron Reports Second Quarter 2008 Financial and Operating Results
Read more →REGNSanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology
Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology
Read more →REGNRegeneron Reports First Quarter 2008 Financial and Operating Results
Regeneron Reports First Quarter 2008 Financial and Operating Results
Read more →REGNFDA Approves Regeneron’s ARCALYST™ (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) First therapy approved for this rare, hereditary, inflammatory disease Regeneron to host conference call on Thursday morning, February 28, 2008 at 8:30 a.m. Eastern Time
FDA Approves Regeneron’s ARCALYST™ (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) First therapy approved for this rare, hereditary, inflammatory disease Regeneron to host conference call on Thursday morning, February 28, 2008 at 8:30 a.m. Eastern Time
Read more →REGNRegeneron Reports Fourth Quarter and Full Year 2007 Financial and Operating Results
Regeneron Reports Fourth Quarter and Full Year 2007 Financial and Operating Results
Read more →REGNRegeneron Closes $312 Million Common Stock Sale in Connection with Sanofi-Aventis Collaboration
Regeneron Closes $312 Million Common Stock Sale in Connection with Sanofi-Aventis Collaboration
Read more →REGNRegeneron Initiates Major Global Collaboration with Sanofi-aventis to Develop and Commercialize Fully-Human Therapeutic Antibodies Sanofi-aventis plans to increase its stake in Regeneron to approximately 19%
Regeneron Initiates Major Global Collaboration with Sanofi-aventis to Develop and Commercialize Fully-Human Therapeutic Antibodies Sanofi-aventis plans to increase its stake in Regeneron to approximately 19%
Read more →REGNRegeneron Reports Third Quarter Financial and Operating Results
Regeneron Reports Third Quarter Financial and Operating Results
Read more →REGNPDUFA Date for Rilonacept (IL-1 Trap) Extended Three Months by FDA Action Date on Biologics License Application Extended to February 29, 2008
PDUFA Date for Rilonacept (IL-1 Trap) Extended Three Months by FDA Action Date on Biologics License Application Extended to February 29, 2008
Read more →REGNRegeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration Data presented at Retina Society Conference in Boston
Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration Data presented at Retina Society Conference in Boston
Read more →REGNRegeneron Receives $20 Million Milestone Payment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD
Regeneron Receives $20 Million Milestone Payment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD
Read more →REGNRilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS Regeneron’s first marketing application is accepted for review by the FDA
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS Regeneron’s first marketing application is accepted for review by the FDA
Read more →REGNRegeneron Reports Second Quarter Financial and Operating Results
Regeneron Reports Second Quarter Financial and Operating Results
Read more →REGNAnnual Meeting of Shareholders
Annual Meeting of Shareholders
Read more →REGNREGENERON REPORTS FIRST QUARTER FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS FIRST QUARTER FINANCIAL AND OPERATING RESULTS
Read more →REGNASTELLAS LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES
ASTELLAS LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES
Read more →REGNREGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2006 FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2006 FINANCIAL AND OPERATING RESULTS
Read more →REGNASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years
ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years
Read more →REGNRegeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody
Read more →REGNREGENERON SIGNS LEASE FOR NEW HEADQUARTERS FACILITY TO BE BUILT IN WESTCHESTER COUNTY, NY
REGENERON SIGNS LEASE FOR NEW HEADQUARTERS FACILITY TO BE BUILT IN WESTCHESTER COUNTY, NY
Read more →REGNLEASE EX-99.1 EXHIBIT 99.1 LEASE by and between BMR-Landmark at Eastview LLC, a Delaware limited liability company and
LEASE EX-99.1 EXHIBIT 99.1 LEASE by and between BMR-Landmark at Eastview LLC, a Delaware limited liability company and
Read more →REGNREGENERON ANNOUNCES CLOSING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK
REGENERON ANNOUNCES CLOSING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK
Read more →REGNREGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS
Read more →REGNREGENERON REPORTS POSITIVE PHASE 3 DATA FOR IL-1 TRAP IN CAPS IL-1 Trap (rilonacept) Markedly Reduced Disease Activity in Patients with Rare Chronic Autoinflammatory Disease
REGENERON REPORTS POSITIVE PHASE 3 DATA FOR IL-1 TRAP IN CAPS IL-1 Trap (rilonacept) Markedly Reduced Disease Activity in Patients with Rare Chronic Autoinflammatory Disease
Read more →REGNBayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases Regeneron Retains U.S. Commercialization Rights, Receives
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases Regeneron Retains U.S. Commercialization Rights, Receives
Read more →REGNNIH SELECTS REGENERON FOR KNOCKOUT MOUSE PROJECT Regeneron Will Use its VelociGene Technology to Target 3,500 Genes Over Five Years, Providing New Models of Human Diseases
NIH SELECTS REGENERON FOR KNOCKOUT MOUSE PROJECT Regeneron Will Use its VelociGene Technology to Target 3,500 Genes Over Five Years, Providing New Models of Human Diseases
Read more →REGNREGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007
REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007
Read more →REGNRegeneron Pharmaceuticals, Inc. Annual Shareholders Meeting
Regeneron Pharmaceuticals, Inc. Annual Shareholders Meeting
Read more →REGNREGENERON RECEIVES FAST-TRACK DESIGNATION FOR THE IL-1 TRAP IN CIAS 1-ASSOCIATED PERIODIC SYNDROMES (CAPS) Data from Pivotal Trial Expected in Second Half of 2006
REGENERON RECEIVES FAST-TRACK DESIGNATION FOR THE IL-1 TRAP IN CIAS 1-ASSOCIATED PERIODIC SYNDROMES (CAPS) Data from Pivotal Trial Expected in Second Half of 2006
Read more →REGNRegeneron Reports First Quarter Financial and Operating Results
Regeneron Reports First Quarter Financial and Operating Results
Read more →REGNREGENERON REPORTS POSITIVE PHASE 1 DATA FOR THE VEGF TRAP IN AGE-RELATED MACULAR DEGENERATION Preliminary results show improvements in vision and retinal swelling VEGF Trap was well tolerated at all dose levels Company also announces initiation of phase 2 trial
REGENERON REPORTS POSITIVE PHASE 1 DATA FOR THE VEGF TRAP IN AGE-RELATED MACULAR DEGENERATION Preliminary results show improvements in vision and retinal swelling VEGF Trap was well tolerated at all dose levels Company also announces initiation of phase 2 trial
Read more →REGNREGENERON COMPLETES ENROLLMENT FOR IL-1 TRAP PHASE 3 TRIAL IN AUTOINFLAMMATORY DISEASE Efficacy Phase of Trial on Target for Completion in 2006
REGENERON COMPLETES ENROLLMENT FOR IL-1 TRAP PHASE 3 TRIAL IN AUTOINFLAMMATORY DISEASE Efficacy Phase of Trial on Target for Completion in 2006
Read more →REGNREGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2005 FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2005 FINANCIAL AND OPERATING RESULTS
Read more →REGNREGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION Phase 1 Preliminary Results to be Presented at the Angiogenesis 2006 Meeting sponsored by Bascom Palmer Eye Institute
REGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION Phase 1 Preliminary Results to be Presented at the Angiogenesis 2006 Meeting sponsored by Bascom Palmer Eye Institute
Read more →REGNREGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS
Read more →REGNREGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS FROM SINGLE-AGENT PHASE 1 TRIAL IN PATIENTS WITH ADVANCED CANCER Results Presented at ASCO Annual Meeting on May 16, 2005
REGENERON’S VEGF TRAP DEMONSTRATES POSITIVE PRELIMINARY RESULTS FROM SINGLE-AGENT PHASE 1 TRIAL IN PATIENTS WITH ADVANCED CANCER Results Presented at ASCO Annual Meeting on May 16, 2005
Read more →REGNREGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2004 FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2004 FINANCIAL AND OPERATING RESULTS
Read more →REGNSANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment
SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment
Read more →REGNREGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS FDA Grants Fast Track Designation to the VEGF Trap for Specific Cancer Indication
REGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS FDA Grants Fast Track Designation to the VEGF Trap for Specific Cancer Indication
Read more →REGNREGENERON ANNOUNCES PLANS FOR PHASE IIb STUDY OF IL-1 TRAP AND END OF NOVARTIS PARTICIPATION IN IL-1 TRAP PROGRAM Phase IIb Study in Rheumatoid Arthritis Planned for Second Half of 2004
REGENERON ANNOUNCES PLANS FOR PHASE IIb STUDY OF IL-1 TRAP AND END OF NOVARTIS PARTICIPATION IN IL-1 TRAP PROGRAM Phase IIb Study in Rheumatoid Arthritis Planned for Second Half of 2004
Read more →REGNREGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2003 FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2003 FINANCIAL AND OPERATING RESULTS
Read more →REGNREGENERON REPORTS PHASE II RESULTS FOR IL-1 TRAP CLINICAL PROGRAM IN RHEUMATOID ARTHRITIS IL-1 Trap Phase II Study Demonstrates Clinical Activity and Favorable Safety and Tolerability Profile
REGENERON REPORTS PHASE II RESULTS FOR IL-1 TRAP CLINICAL PROGRAM IN RHEUMATOID ARTHRITIS IL-1 Trap Phase II Study Demonstrates Clinical Activity and Favorable Safety and Tolerability Profile
Read more →REGNAVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY
AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY
Read more →REGNREGENERON’S AXOKINE PROMOTES WEIGHT LOSS IN STUDY OF OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES
REGENERON’S AXOKINE PROMOTES WEIGHT LOSS IN STUDY OF OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES
Read more →REGNRegeneron Announces Results of Phase III Obesity Study
Regeneron Announces Results of Phase III Obesity Study
Read more →REGNREGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally
REGENERON AND NOVARTIS FORM STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE THE IL-1 TRAP IN RHEUMATOID ARTHRITIS AND OTHER INDICATIONS Novartis to Pay Regeneron $27 Million and Will Make $48 Million Equity Investment in Regeneron Novartis to Provide 100% Funding for Clinical Development and Provide Manufacturing Facility for Commercial Product Needs Companies Will Have Co-promotion Rights and Will Share Profits Equally
Read more →REGNREGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2002 FINANCIAL AND OPERATING RESULTS
REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2002 FINANCIAL AND OPERATING RESULTS
Read more →REGNREGENERON COMPLETES 12-MONTH EFFICACY PHASE OF AXOKINE(R) PHASE III PIVOTAL TRIAL FOR THE TREATMENT OF OBESITY
REGENERON COMPLETES 12-MONTH EFFICACY PHASE OF AXOKINE(R) PHASE III PIVOTAL TRIAL FOR THE TREATMENT OF OBESITY
Read more →REGNREGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM
REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM
Read more →REGNARTHUR F. RYAN ELECTED TO REGENERON'S BOARD OF DIRECTORS
ARTHUR F. RYAN ELECTED TO REGENERON'S BOARD OF DIRECTORS
Read more →REGNREGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic
REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP IN PATIENTS WITH RHEUMATOID ARTHRITIS Lead Compound in Regeneron's Custom-designed Trap Program Advances in Clinic
Read more →REGNREGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT
REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT
Read more →REGNREGENERON GRANTED LICENSE BY AMGEN AND IMMUNEX TO INTERLEUKIN-1 INHIBITOR PATENTS
REGENERON GRANTED LICENSE BY AMGEN AND IMMUNEX TO INTERLEUKIN-1 INHIBITOR PATENTS
Read more →REGNREGENERON ANNOUNCES OFFERING OF CONVERTIBLE SENIOR SUBORDINATED NOTES IN A 144A OFFERING
REGENERON ANNOUNCES OFFERING OF CONVERTIBLE SENIOR SUBORDINATED NOTES IN A 144A OFFERING
Read more →REGNREGENERON SELLS $200 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES
REGENERON SELLS $200 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES
Read more →REGNREGENERON ANNOUNCES OPERATING RESULTS
REGENERON ANNOUNCES OPERATING RESULTS
Read more →Competitive Position
How REGN ranks across every disease it competes inCompetitive Position is a premium feature
See how REGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial